	motif	n	raw_pos	kabat_pos	imgt_pos	in_germline	region	chain_type	inn_number	seq_id	germline_gene	germline_family	antibody	species	seq
site1	DG	N	54	H54	H62	False	CDR2	H	8659	8659_seq1	IGHV1-3*01	IGHV1	abagovomab	Mouse	QVKLQESGAELARPGASVKLSCKASGYTFTNYWMQWVKQRPGQGLDWIGAIYPGDGNTRYTHKFKGKATLTADKSSSTAYMQLSSLASEDSGVYYCARGEGNYAWFAYWGQGTTVTVSS
site2	DG	N+1	55	H55	H63	True	CDR2	H	8659	8659_seq1	IGHV1-3*01	IGHV1	abagovomab	Mouse	QVKLQESGAELARPGASVKLSCKASGYTFTNYWMQWVKQRPGQGLDWIGAIYPGDGNTRYTHKFKGKATLTADKSSSTAYMQLSSLASEDSGVYYCARGEGNYAWFAYWGQGTTVTVSS
site3	DG	N	53	H54	H59	False	CDR2	H	10745	10745_seq1	IGHV2-26*01	IGHV2	abrezekimab	Humanized	QVTLKESGPVLVKPTETLTLTCTVSGFSLTNYHVQWIRQPPGKALEWLGVMWSDGDTSFNSVLKSRLTISRDTSKSQVVLTMTNMDPVDTATYYCARDGTIAAMDYFDYWGQGTLVTVSS
site4	DG	N+1	54	H55	H63	False	CDR2	H	10745	10745_seq1	IGHV2-26*01	IGHV2	abrezekimab	Humanized	QVTLKESGPVLVKPTETLTLTCTVSGFSLTNYHVQWIRQPPGKALEWLGVMWSDGDTSFNSVLKSRLTISRDTSKSQVVLTMTNMDPVDTATYYCARDGTIAAMDYFDYWGQGTLVTVSS
site5	DG	N	97	H95	H107	False	CDR3	H	10745	10745_seq1	IGHV2-26*01	IGHV2	abrezekimab	Humanized	QVTLKESGPVLVKPTETLTLTCTVSGFSLTNYHVQWIRQPPGKALEWLGVMWSDGDTSFNSVLKSRLTISRDTSKSQVVLTMTNMDPVDTATYYCARDGTIAAMDYFDYWGQGTLVTVSS
site6	DG	N+1	98	H96	H108	False	CDR3	H	10745	10745_seq1	IGHV2-26*01	IGHV2	abrezekimab	Humanized	QVTLKESGPVLVKPTETLTLTCTVSGFSLTNYHVQWIRQPPGKALEWLGVMWSDGDTSFNSVLKSRLTISRDTSKSQVVLTMTNMDPVDTATYYCARDGTIAAMDYFDYWGQGTLVTVSS
site7	DG	N	54	H54	H62	True	CDR2	H	9921	9921_seq1	IGHV1-24*01	IGHV1	abrilumab	Human	QVQLVQSGAEVKKPGASVKVSCKVSGYTLSDLSIHWVRQAPGKGLEWMGGFDPQDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLKSEDTAVYYCATGSSSSWFDPWGQGTLVTVSS
site8	DG	N+1	55	H55	H63	True	CDR2	H	9921	9921_seq1	IGHV1-24*01	IGHV1	abrilumab	Human	QVQLVQSGAEVKKPGASVKVSCKVSGYTLSDLSIHWVRQAPGKGLEWMGGFDPQDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLKSEDTAVYYCATGSSSSWFDPWGQGTLVTVSS
site9	NG	N	54	H54	H62	True	CDR2	H	11089	11089_seq1	IGHV1-3*01	IGHV1	actinium (225Ac) lintuzumab satetraxetan	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYNMHWVRQAPGQGLEWIGYIYPYNGGTGYNQKFKSKATITADESTNTAYMELSSLRSEDTAVYYCARGRPAMDYWGQGTLVTVSS
site10	NG	N+1	55	H55	H63	True	CDR2	H	11089	11089_seq1	IGHV1-3*01	IGHV1	actinium (225Ac) lintuzumab satetraxetan	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYNMHWVRQAPGQGLEWIGYIYPYNGGTGYNQKFKSKATITADESTNTAYMELSSLRSEDTAVYYCARGRPAMDYWGQGTLVTVSS
site11	DG	N	53	H53	H59	True	CDR2	H	9568	9568_seq1	IGHV3-33*01	IGHV3	actoxumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFSFSNYGMHWVRQAPGKGLEWVALIWYDGSNEDYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWGMVRGVIDVFDIWGQGTVVTVSS
site12	DG	N+1	54	H54	H62	True	CDR2	H	9568	9568_seq1	IGHV3-33*01	IGHV3	actoxumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFSFSNYGMHWVRQAPGKGLEWVALIWYDGSNEDYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWGMVRGVIDVFDIWGQGTVVTVSS
site13	DG	N	53	H53	H59	True	CDR2	H	9838	9838_seq2	IGHV3-33*01	IGHV3	aducanumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWFDGTKKYYTDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDRGIGARRGPYYMDVWGKGTTVTVSS
site14	DG	N+1	54	H54	H62	True	CDR2	H	9838	9838_seq2	IGHV3-33*01	IGHV3	aducanumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWFDGTKKYYTDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDRGIGARRGPYYMDVWGKGTTVTVSS
site15	NG	N	54	H54	H62	True	CDR2	H	9343	9343_seq1	IGHV1-3*01	IGHV1	amatuximab	Chimeric	QVQLQQSGPELEKPGASVKISCKASGYSFTGYTMNWVKQSHGKSLEWIGLITPYNGASSYNQKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDYWGSGTPVTVSS
site16	NG	N+1	55	H55	H63	True	CDR2	H	9343	9343_seq1	IGHV1-3*01	IGHV1	amatuximab	Chimeric	QVQLQQSGPELEKPGASVKISCKASGYSFTGYTMNWVKQSHGKSLEWIGLITPYNGASSYNQKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDYWGSGTPVTVSS
site17	DG	N	101	H98	H110	False	CDR3	H	9343	9343_seq1	IGHV1-3*01	IGHV1	amatuximab	Chimeric	QVQLQQSGPELEKPGASVKISCKASGYSFTGYTMNWVKQSHGKSLEWIGLITPYNGASSYNQKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDYWGSGTPVTVSS
site18	DG	N+1	102	H99	H112	False	CDR3	H	9343	9343_seq1	IGHV1-3*01	IGHV1	amatuximab	Chimeric	QVQLQQSGPELEKPGASVKISCKASGYSFTGYTMNWVKQSHGKSLEWIGLITPYNGASSYNQKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDYWGSGTPVTVSS
site19	DG	N	53	H53	H59	True	CDR2	H	11030	11030_seq1	IGHV3-33*01	IGHV3	amivantamab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS
site20	DG	N+1	54	H54	H62	True	CDR2	H	11030	11030_seq1	IGHV3-33*01	IGHV3	amivantamab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS
site21	DG	N	98	H95	H107	False	CDR3	H	11030	11030_seq1	IGHV3-33*01	IGHV3	amivantamab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS
site22	DG	N+1	99	H96	H108	False	CDR3	H	11030	11030_seq1	IGHV3-33*01	IGHV3	amivantamab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS
site23	NG	N	54	H54	H62	True	CDR2	H	11030	11030_seq2	IGHV1-18*01	IGHV1	amivantamab	Human	QVQLVQSGAEVKKPGASVKVSCETSGYTFTSYGISWVRQAPGHGLEWMGWISAYNGYTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDLRGTNYFDYWGQGTLVTVSS
site24	NG	N+1	55	H55	H63	True	CDR2	H	11030	11030_seq2	IGHV1-18*01	IGHV1	amivantamab	Human	QVQLVQSGAEVKKPGASVKVSCETSGYTFTSYGISWVRQAPGHGLEWMGWISAYNGYTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDLRGTNYFDYWGQGTLVTVSS
site25	DG	N	107	H101	H116	True	CDR3	H	11111	11111_seq2	IGHV5-51*01	IGHV5	anetumab corixetan	Human	QVELVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQAPGKGLEWMGIIDPGDSRTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGQLYGGTYMDGWGQGTLVTVSS
site26	DG	N+1	108	H102	H117	False	CDR3	H	11111	11111_seq2	IGHV5-51*01	IGHV5	anetumab corixetan	Human	QVELVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQAPGKGLEWMGIIDPGDSRTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGQLYGGTYMDGWGQGTLVTVSS
site27	DG	N	107	H101	H116	True	CDR3	H	9788	9788_seq2	IGHV5-51*01	IGHV5	anetumab ravtansine	Human	QVELVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQAPGKGLEWMGIIDPGDSRTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGQLYGGTYMDGWGQGTLVTVSS
site28	DG	N+1	108	H102	H117	False	CDR3	H	9788	9788_seq2	IGHV5-51*01	IGHV5	anetumab ravtansine	Human	QVELVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQAPGKGLEWMGIIDPGDSRTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGQLYGGTYMDGWGQGTLVTVSS
site29	DG	N	98	H96	H108	False	CDR3	H	8942	8942_seq1	IGHV3/OR16-10*03	IGHV3	anrukinzumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFTFISYAMSWVRQAPGKGLEWVASISSGGNTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLDGYYFGFAYWGQGTLVTVSS
site30	DG	N+1	99	H97	H109	False	CDR3	H	8942	8942_seq1	IGHV3/OR16-10*03	IGHV3	anrukinzumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFTFISYAMSWVRQAPGKGLEWVASISSGGNTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLDGYYFGFAYWGQGTLVTVSS
site31	DG	N	53	H53	H59	True	CDR2	H	9336	9336_seq1	IGHV3-7*01	IGHV3	atinumab	Human	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMSWVRQAPGKGLEWVATIKQDGSQKNYVDSVKGRFTISRDNAKNSLYLRLNSLRAEDTAVYYCATELFDLWGRGSLVTVSS
site32	DG	N+1	54	H54	H62	True	CDR2	H	9336	9336_seq1	IGHV3-7*01	IGHV3	atinumab	Human	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMSWVRQAPGKGLEWVATIKQDGSQKNYVDSVKGRFTISRDNAKNSLYLRLNSLRAEDTAVYYCATELFDLWGRGSLVTVSS
site33	DG	N	53	H53	H59	True	CDR2	H	11032	11032_seq2	IGHV3-33*01	IGHV3	atoltivimab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFNNYGMHWVRQAPGMGLEWVAVIWHDGSDKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARNWNLFDYWGQGTLVTVSS
site34	DG	N+1	54	H54	H62	True	CDR2	H	11032	11032_seq2	IGHV3-33*01	IGHV3	atoltivimab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFNNYGMHWVRQAPGMGLEWVAVIWHDGSDKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARNWNLFDYWGQGTLVTVSS
site35	NG	N	32	L28	L34	False	CDR1	K	10498	10498_seq1	IGKV2D-29*02	IGKV2D	azintuxizumab	Humanized/Chimeric	DVVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPPFTFGGGTKVEIK
site36	NG	N+1	33	L29	L35	True	CDR1	K	10498	10498_seq1	IGKV2D-29*02	IGKV2D	azintuxizumab	Humanized/Chimeric	DVVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPPFTFGGGTKVEIK
site37	DG	N	53	H53	H59	True	CDR2	H	10498	10498_seq2	IGHV3-7*01	IGHV3	azintuxizumab	Humanized/Chimeric	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMAWVRQAPGKGLEWVASINYDGSSTYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRGYYFDYWGQGTTVTVSS
site38	DG	N+1	54	H54	H62	True	CDR2	H	10498	10498_seq2	IGHV3-7*01	IGHV3	azintuxizumab	Humanized/Chimeric	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMAWVRQAPGKGLEWVASINYDGSSTYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRGYYFDYWGQGTTVTVSS
site39	NG	N	32	L28	L34	False	CDR1	K	10499	10499_seq1	IGKV2D-29*02	IGKV2D	azintuxizumab vedotin	Humanized/Chimeric	DVVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPPFTFGGGTKVEIK
site40	NG	N+1	33	L29	L35	True	CDR1	K	10499	10499_seq1	IGKV2D-29*02	IGKV2D	azintuxizumab vedotin	Humanized/Chimeric	DVVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPPFTFGGGTKVEIK
site41	DG	N	53	H53	H59	True	CDR2	H	10499	10499_seq2	IGHV3-7*01	IGHV3	azintuxizumab vedotin	Humanized/Chimeric	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMAWVRQAPGKGLEWVASINYDGSSTYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRGYYFDYWGQGTTVTVSS
site42	DG	N+1	54	H54	H62	True	CDR2	H	10499	10499_seq2	IGHV3-7*01	IGHV3	azintuxizumab vedotin	Humanized/Chimeric	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMAWVRQAPGKGLEWVASINYDGSSTYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRGYYFDYWGQGTTVTVSS
site43	NG	N	98	H95	H107	False	CDR3	H	10993	10993_seq2	IGHV3-33*01	IGHV3	balstilimab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASNGDHWGQGTLVTVSS
site44	NG	N+1	99	H96	H115	False	CDR3	H	10993	10993_seq2	IGHV3-33*01	IGHV3	balstilimab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASNGDHWGQGTLVTVSS
site45	DG	N	53	H53	H59	True	CDR2	H	10993	10993_seq2	IGHV3-33*01	IGHV3	balstilimab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASNGDHWGQGTLVTVSS
site46	DG	N+1	54	H54	H62	True	CDR2	H	10993	10993_seq2	IGHV3-33*01	IGHV3	balstilimab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASNGDHWGQGTLVTVSS
site47	DG	N	32	L28	L34	True	CDR1	K	8624	8624_seq2	IGKV2-29*02	IGKV2	bapineuzumab	Humanized	DVVMTQSPLSLPVTPGEPASISCKSSQSLLDSDGKTYLNWLLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPRTFGQGTKVEIK
site48	DG	N+1	33	L29	L35	True	CDR1	K	8624	8624_seq2	IGKV2-29*02	IGKV2	bapineuzumab	Humanized	DVVMTQSPLSLPVTPGEPASISCKSSQSLLDSDGKTYLNWLLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPRTFGQGTKVEIK
site49	DG	N	54	H54	H62	False	CDR2	H	9959	9959_seq2	IGHV1-3*01	IGHV1	begelomab	Mouse	QVQLQQSGAELVKPGASVKLSCKASGYTFRSYDINWVRQRPEQGLEWIGWIFPGDGSTKYNEKFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCARWTVVGPGYFDVWGAGTTVTVSS
site50	DG	N+1	55	H55	H63	True	CDR2	H	9959	9959_seq2	IGHV1-3*01	IGHV1	begelomab	Mouse	QVQLQQSGAELVKPGASVKLSCKASGYTFRSYDINWVRQRPEQGLEWIGWIFPGDGSTKYNEKFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCARWTVVGPGYFDVWGAGTTVTVSS
site51	DG	N	102	H99	H111	False	CDR3	H	10797	10797_seq1	IGHV1-69*02	IGHV1	belantamab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLDNWGQGTLVTVSS
site52	DG	N+1	103	H100	H112A	False	CDR3	H	10797	10797_seq1	IGHV1-69*02	IGHV1	belantamab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLDNWGQGTLVTVSS
site53	DG	N	102	H99	H111	False	CDR3	H	10754	10754_seq1	IGHV1-69*02	IGHV1	belantamab mafodotin	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLDNWGQGTLVTVSS
site54	DG	N+1	103	H100	H112A	False	CDR3	H	10754	10754_seq1	IGHV1-69*02	IGHV1	belantamab mafodotin	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLDNWGQGTLVTVSS
site55	NG	N	54	H54	H62	False	CDR2	H	10681	10681_seq1	IGHV1-46*01	IGHV1	bemarituzumab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYIFTTYNVHWVRQAPGQGLEWIGSIYPDNGDTSYNQNFKGRATITADKSTSTAYMELSSLRSEDTAVYYCARGDFAYWGQGTLVTVSS
site56	NG	N+1	55	H55	H63	True	CDR2	H	10681	10681_seq1	IGHV1-46*01	IGHV1	bemarituzumab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYIFTTYNVHWVRQAPGQGLEWIGSIYPDNGDTSYNQNFKGRATITADKSTSTAYMELSSLRSEDTAVYYCARGDFAYWGQGTLVTVSS
site57	DG	N	55	H55	H63	False	CDR2	H	9233	9233_seq1	IGHV1-46*01	IGHV1	benralizumab	Humanized	EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVSS
site58	DG	N+1	56	H56	H64	False	CDR2	H	9233	9233_seq1	IGHV1-46*01	IGHV1	benralizumab	Humanized	EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVSS
site59	DG	N	32	L28	L34	True	CDR1	K	11224	11224_seq1	IGKV2-29*02	IGKV2	bepranemab	Humanized	DIVMTQTPLSLSVTPGQPASISCRSSQSLEYSDGYTYLEWYLQKPGQSPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQATHNPYTFGQGTKLEIK
site60	DG	N+1	33	L29	L35	True	CDR1	K	11224	11224_seq1	IGKV2-29*02	IGKV2	bepranemab	Humanized	DIVMTQTPLSLSVTPGQPASISCRSSQSLEYSDGYTYLEWYLQKPGQSPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQATHNPYTFGQGTKLEIK
site61	DG	N	53	H54	H59	False	CDR2	H	11224	11224_seq2	IGHV4-4*08	IGHV4	bepranemab	Humanized	EVQLQESGPGLVKPSETLSLTCTVSGFSLTSNDIAWIRQPPGKGLEWMGTIWTDGSTNYNTAVQSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHRLYYGAFDYWGQGTMVTVSS
site62	DG	N+1	54	H55	H63	True	CDR2	H	11224	11224_seq2	IGHV4-4*08	IGHV4	bepranemab	Humanized	EVQLQESGPGLVKPSETLSLTCTVSGFSLTSNDIAWIRQPPGKGLEWMGTIWTDGSTNYNTAVQSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHRLYYGAFDYWGQGTMVTVSS
site63	DG	N	53	H53	H59	True	CDR2	H	10806	10806_seq2	IGHV3-30*03	IGHV3	bermekimab	Humanized	QVQLVESGGGVVQPGRSLRLSCTASGFTFSMFGVHWVRQAPGKGLEWVAAVSYDGSNKYYAESVKGRFTISRDNSKNILFLQMDSLRLEDTAVYYCARGRPKVVIPAPLAHWGQGTLVTFSS
site64	DG	N+1	54	H54	H62	True	CDR2	H	10806	10806_seq2	IGHV3-30*03	IGHV3	bermekimab	Humanized	QVQLVESGGGVVQPGRSLRLSCTASGFTFSMFGVHWVRQAPGKGLEWVAAVSYDGSNKYYAESVKGRFTISRDNSKNILFLQMDSLRLEDTAVYYCARGRPKVVIPAPLAHWGQGTLVTFSS
site65	DG	N	53	H53	H59	True	CDR2	H	10709	10709_seq1	IGHV3-30*02	IGHV3	bersanlimab	Human	EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVAFIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYSGWYFDYWGQGTLVTVSS
site66	DG	N+1	54	H54	H62	True	CDR2	H	10709	10709_seq1	IGHV3-30*02	IGHV3	bersanlimab	Human	EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVAFIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYSGWYFDYWGQGTLVTVSS
site67	DG	N	53	H53	H59	True	CDR2	H	10425	10425_seq1	IGHV3-33*01	IGHV3	brazikumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNEYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGYTSSWYPDAFDIWGQGTMVTVSS
site68	DG	N+1	54	H54	H62	True	CDR2	H	10425	10425_seq1	IGHV3-33*01	IGHV3	brazikumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNEYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGYTSSWYPDAFDIWGQGTMVTVSS
site69	DG	N	31	L28	L34	False	CDR1	K	9144	9144_seq2	IGKV7-3*01	IGKV7	brentuximab vedotin	Chimeric	DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPKVLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK
site70	DG	N+1	32	L29	L35	True	CDR1	K	9144	9144_seq2	IGKV7-3*01	IGKV7	brentuximab vedotin	Chimeric	DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPKVLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK
site71	DG	N	53	H53	H59	True	CDR2	H	9153	9153_seq2	IGHV3-30*02	IGHV3	briakinumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSS
site72	DG	N+1	54	H54	H62	True	CDR2	H	9153	9153_seq2	IGHV3-30*02	IGHV3	briakinumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSS
site73	DG	N	99	H96	H108	False	CDR3	H	9982	9982_seq2	IGHV1-24*01	IGHV1	brontictuzumab	Humanized	QVQLVQSGAEVKKPGASVKISCKVSGYTLRGYWIEWVRQAPGKGLEWIGQILPGTGRTNYNEKFKGRVTMTADTSTDTAYMELSSLRSEDTAVYYCARFDGNYGYYAMDYWGQGTTVTVSS
site74	DG	N+1	100	H97	H109	False	CDR3	H	9982	9982_seq2	IGHV1-24*01	IGHV1	brontictuzumab	Humanized	QVQLVQSGAEVKKPGASVKISCKVSGYTLRGYWIEWVRQAPGKGLEWIGQILPGTGRTNYNEKFKGRVTMTADTSTDTAYMELSSLRSEDTAVYYCARFDGNYGYYAMDYWGQGTTVTVSS
site75	DG	N	31	L28	L34	False	CDR1	K	10121	10121_seq1	IGKV3-11*01	IGKV3	cabiralizumab	Humanized	EIVLTQSPATLSLSPGERATLSCKASQSVDYDGDNYMNWYQQKPGQAPRLLIYAASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHLSNEDLSTFGGGTKVEIK
site76	DG	N+1	32	L29	L35	False	CDR1	K	10121	10121_seq1	IGKV3-11*01	IGKV3	cabiralizumab	Humanized	EIVLTQSPATLSLSPGERATLSCKASQSVDYDGDNYMNWYQQKPGQAPRLLIYAASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHLSNEDLSTFGGGTKVEIK
site77	NG	N	54	H54	H62	False	CDR2	H	10121	10121_seq2	IGHV1-46*01	IGHV1	cabiralizumab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVRQAPGQGLEWMGDINPYNGGTTFNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARESPYFSNLYVMDYWGQGTLVTVSS
site78	NG	N+1	55	H55	H63	True	CDR2	H	10121	10121_seq2	IGHV1-46*01	IGHV1	cabiralizumab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVRQAPGQGLEWMGDINPYNGGTTFNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARESPYFSNLYVMDYWGQGTLVTVSS
site79	DG	N	53	H53	H59	True	CDR2	H	8836	8836_seq2	IGHV3-33*01	IGHV3	canakinumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSS
site80	DG	N+1	54	H54	H62	True	CDR2	H	8836	8836_seq2	IGHV3-33*01	IGHV3	canakinumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSS
site81	NG	N	32	L28	L34	True	CDR1	K	9441	9441_seq2	IGKV2-28*01	IGKV2	cantuzumab ravtansine	Humanized	DIVMTQSPLSVPVTPGEPVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLVSGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCLQHLEYPFTFGPGTKLELK
site82	NG	N+1	33	L29	L35	True	CDR1	K	9441	9441_seq2	IGKV2-28*01	IGKV2	cantuzumab ravtansine	Humanized	DIVMTQSPLSVPVTPGEPVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLVSGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCLQHLEYPFTFGPGTKLELK
site83	DG	N	99	H96	H108	False	CDR3	H	9372	9372_seq1	IGHV1-69*01	IGHV1	carlumab	Human	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDGIYGELDFWGQGTLVTVSS
site84	DG	N+1	100	H97	H109	False	CDR3	H	9372	9372_seq1	IGHV1-69*01	IGHV1	carlumab	Human	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDGIYGELDFWGQGTLVTVSS
site85	DG	N	98	H95	H107	False	CDR3	H	11258	11258_seq4	IGHV1-3*01	IGHV1	cevostamab	Humanized/Chimeric	EVQLVQSGAEVKKPGASVKVSCKASGFTFTSYYIHWVRQAPGQGLEWIGWIYPENDNTKYNEKFKDRVTITADTSTSTAYLELSSLRSEDTAVYYCARDGYSRYYFDYWGQGTLVTVSS
site86	DG	N+1	99	H96	H108	False	CDR3	H	11258	11258_seq4	IGHV1-3*01	IGHV1	cevostamab	Humanized/Chimeric	EVQLVQSGAEVKKPGASVKVSCKASGFTFTSYYIHWVRQAPGQGLEWIGWIYPENDNTKYNEKFKDRVTITADTSTSTAYLELSSLRSEDTAVYYCARDGYSRYYFDYWGQGTLVTVSS
site87	DG	N	55	H53	H61	True	CDR2	H	11777	11777_seq2	IGHV3-15*01	IGHV3	cilgavimab	Human	EVQLVESGGGLVKPGGSLRLSCAASGFTFRDVWMSWVRQAPGKGLEWVGRIKSKIDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTAGSYYYDTVGPGLPEGKFDYWGQGTLVTVSS
site88	DG	N+1	56	H54	H62	True	CDR2	H	11777	11777_seq2	IGHV3-15*01	IGHV3	cilgavimab	Human	EVQLVESGGGLVKPGGSLRLSCAASGFTFRDVWMSWVRQAPGKGLEWVGRIKSKIDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTAGSYYYDTVGPGLPEGKFDYWGQGTLVTVSS
site89	DG	N	55	H53	H61	True	CDR2	H	11043	11043_seq1	IGHV3-15*01	IGHV3	cinpanemab	Humanized	EVQLVESGGGLVEPGGSLRLSCAVSGFDFEKAWMSWVRQAPGQGLQWVARIKSTADGGTTSYAAPVEGRFIISRDDSRNMLYLQMNSLKTEDTAVYYCTSAHWGQGTLVTVSS
site90	DG	N+1	56	H54	H62	True	CDR2	H	11043	11043_seq1	IGHV3-15*01	IGHV3	cinpanemab	Humanized	EVQLVESGGGLVEPGGSLRLSCAVSGFDFEKAWMSWVRQAPGQGLQWVARIKSTADGGTTSYAAPVEGRFIISRDDSRNMLYLQMNSLKTEDTAVYYCTSAHWGQGTLVTVSS
site91	NG	N	54	H54	H62	False	CDR2	H	11094	11094_seq1	IGHV3-66*01	IGHV3	cinrebafusp alfa	Chimeric	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site92	NG	N+1	55	H55	H63	True	CDR2	H	11094	11094_seq1	IGHV3-66*01	IGHV3	cinrebafusp alfa	Chimeric	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site93	DG	N	101	H98	H110	False	CDR3	H	11094	11094_seq1	IGHV3-66*01	IGHV3	cinrebafusp alfa	Chimeric	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site94	DG	N+1	102	H99	H111	False	CDR3	H	11094	11094_seq1	IGHV3-66*01	IGHV3	cinrebafusp alfa	Chimeric	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site95	NG	N	32	L28	L34	False	CDR1	K	9046	9046_seq2	IGKV1-39*01	IGKV1	citatuzumab bogatox	Humanized	DIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELK
site96	NG	N+1	33	L29	L35	False	CDR1	K	9046	9046_seq2	IGKV1-39*01	IGKV1	citatuzumab bogatox	Humanized	DIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELK
site97	DG	N	90	L92	L108	True	CDR3	L	9099	9099_seq1	IGLV3-19*01	IGLV3	cixutumumab	Human	SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCKSRDGSGQHLVFGGGTKLTVL
site98	DG	N+1	91	L93	L109	False	CDR3	L	9099	9099_seq1	IGLV3-19*01	IGLV3	cixutumumab	Human	SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCKSRDGSGQHLVFGGGTKLTVL
site99	DG	N	55	H55	H63	False	CDR2	H	10103	10103_seq1	IGHV1-2*02	IGHV1	clivatuzumab tetraxetan	Humanized	QVQLQQSGAEVKKPGASVKVSCEASGYTFPSYVLHWVKQAPGQGLEWIGYINPYNDGTQYNEKFKGKATLTRDTSINTAYMELSRLRSDDTAVYYCARGFGGSYGFAYWGQGTLVTVSS
site100	DG	N+1	56	H56	H64	True	CDR2	H	10103	10103_seq1	IGHV1-2*02	IGHV1	clivatuzumab tetraxetan	Humanized	QVQLQQSGAEVKKPGASVKVSCEASGYTFPSYVLHWVKQAPGQGLEWIGYINPYNDGTQYNEKFKGKATLTRDTSINTAYMELSRLRSDDTAVYYCARGFGGSYGFAYWGQGTLVTVSS
site101	DG	N	32	L28	L34	True	CDR1	K	9636	9636_seq1	IGKV2-29*02	IGKV2	concizumab	Humanized	DIVMTQTPLSLSVTPGQPASISCKSSQSLLESDGKTYLNWYLQKPGQSPQLLIYLVSILDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQATHFPQTFGGGTKVEIK
site102	DG	N+1	33	L29	L35	True	CDR1	K	9636	9636_seq1	IGKV2-29*02	IGKV2	concizumab	Humanized	DIVMTQTPLSLSVTPGQPASISCKSSQSLLESDGKTYLNWYLQKPGQSPQLLIYLVSILDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQATHFPQTFGGGTKVEIK
site103	NG	N	32	L28	L34	True	CDR1	K	9482	9482_seq1	IGKV2-28*01	IGKV2	crenezumab	Humanized	DIVMTQSPLSLPVTPGEPASISCRSSQSLVYSNGDTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK
site104	NG	N+1	33	L29	L35	True	CDR1	K	9482	9482_seq1	IGKV2-28*01	IGKV2	crenezumab	Humanized	DIVMTQSPLSLPVTPGEPASISCRSSQSLVYSNGDTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK
site105	NG	N	53	H53	H59	False	CDR2	H	9482	9482_seq2	IGHV3-23*04	IGHV3	crenezumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLELVASINSNGGSTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASGDYWGQGTTVTVSS
site106	NG	N+1	54	H54	H62	True	CDR2	H	9482	9482_seq2	IGHV3-23*04	IGHV3	crenezumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLELVASINSNGGSTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASGDYWGQGTTVTVSS
site107	DG	N	31	L28	L34	False	CDR1	K	10316	10316_seq1	IGKV1-39*01	IGKV1	crizanlizumab	Humanized	DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGHSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSDENPLTFGGGTKVEIK
site108	DG	N+1	32	L29	L35	False	CDR1	K	10316	10316_seq1	IGKV1-39*01	IGKV1	crizanlizumab	Humanized	DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGHSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSDENPLTFGGGTKVEIK
site109	DG	N	54	H54	H62	False	CDR2	H	10316	10316_seq2	IGHV1-46*01	IGHV1	crizanlizumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKVSGYTFTSYDINWVRQAPGKGLEWMGWIYPGDGSIKYNEKFKGRVTMTVDKSTDTAYMELSSLRSEDTAVYYCARRGEYGNYEGAMDYWGQGTLVTVSS
site110	DG	N+1	55	H55	H63	True	CDR2	H	10316	10316_seq2	IGHV1-46*01	IGHV1	crizanlizumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKVSGYTFTSYDINWVRQAPGKGLEWMGWIYPGDGSIKYNEKFKGRVTMTVDKSTDTAYMELSSLRSEDTAVYYCARRGEYGNYEGAMDYWGQGTLVTVSS
site111	DG	N	53	H53	H59	True	CDR2	H	10196	10196_seq1	IGHV3-7*01	IGHV3	crotedumab	Human	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYLMNWVRQAPGKGLEWLANIQEDGIEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREPSHYDILTGYDYYYGMDVWGQGTTVTVSS
site112	DG	N+1	54	H54	H62	True	CDR2	H	10196	10196_seq1	IGHV3-7*01	IGHV3	crotedumab	Human	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYLMNWVRQAPGKGLEWLANIQEDGIEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREPSHYDILTGYDYYYGMDVWGQGTTVTVSS
site113	DG	N	53	H53	H59	True	CDR2	H	11200	11200_seq2	IGHV3-30*03	IGHV3	cudarolimab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGRPWYSETGTSAFDIWGQGTMVTVSS
site114	DG	N+1	54	H54	H62	True	CDR2	H	11200	11200_seq2	IGHV3-30*03	IGHV3	cudarolimab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGRPWYSETGTSAFDIWGQGTMVTVSS
site115	NG	N	32	L28	L34	False	CDR1	K	8959	8959_seq1	IGKV1-39*01	IGKV1	dacetuzumab	Humanized	DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIK
site116	NG	N+1	33	L29	L35	False	CDR1	K	8959	8959_seq1	IGKV1-39*01	IGKV1	dacetuzumab	Humanized	DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIK
site117	DG	N	54	H54	H59	False	CDR2	H	9200	9200_seq1	IGHV4-59*01	IGHV4	dalotuzumab	Humanized	QVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTLVTVSS
site118	DG	N+1	55	H55	H63	True	CDR2	H	9200	9200_seq1	IGHV4-59*01	IGHV4	dalotuzumab	Humanized	QVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTLVTVSS
site119	NG	N	32	L28	L34	True	CDR1	K	9200	9200_seq2	IGKV2-28*01	IGKV2	dalotuzumab	Humanized	DIVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPWTFGQGTKVEIK
site120	NG	N+1	33	L29	L35	True	CDR1	K	9200	9200_seq2	IGKV2-28*01	IGKV2	dalotuzumab	Humanized	DIVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPWTFGQGTKVEIK
site121	DG	N	53	H54	H59	False	CDR2	H	9869	9869_seq1	IGHV3-66*01	IGHV3	dapirolizumab pegol	Humanized	EVQLVESGGGLVQPGGSLRLSCAVSGFSSTNYHVHWVRQAPGKGLEWMGVIWGDGDTSYNSVLKSRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARQLTHYYVLAAWGQGTLVTVSS
site122	DG	N+1	54	H55	H63	True	CDR2	H	9869	9869_seq1	IGHV3-66*01	IGHV3	dapirolizumab pegol	Humanized	EVQLVESGGGLVQPGGSLRLSCAVSGFSSTNYHVHWVRQAPGKGLEWMGVIWGDGDTSYNSVLKSRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARQLTHYYVLAAWGQGTLVTVSS
site123	DG	N	53	H53	H59	True	CDR2	H	10059	10059_seq2	IGHV3-33*01	IGHV3	dectrekumab	Human	EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLWFGDLDAFDIWGQGTMVTVSS
site124	DG	N+1	54	H54	H62	True	CDR2	H	10059	10059_seq2	IGHV3-33*01	IGHV3	dectrekumab	Human	EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLWFGDLDAFDIWGQGTMVTVSS
site125	NG	N	54	H54	H62	True	CDR2	H	9572	9572_seq2	IGHV1-18*01	IGHV1	demcizumab	Humanized	QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIHWVKQAPGQGLEWIGYISSYNGATNYNQKFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVGMDYWGQGTLVTVSS
site126	NG	N+1	55	H55	H63	True	CDR2	H	9572	9572_seq2	IGHV1-18*01	IGHV1	demcizumab	Humanized	QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIHWVKQAPGQGLEWIGYISSYNGATNYNQKFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVGMDYWGQGTLVTVSS
site127	DG	N	54	H54	H62	False	CDR2	H	10364	10364_seq1	IGHV1-69*02	IGHV1	dezamizumab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGFTFATYNMHWVRQAPGQGLEWMGYIYPGDGNANYNQQFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGDFDYDGGYYFDSWGQGTLVTVSS
site128	DG	N+1	55	H55	H63	True	CDR2	H	10364	10364_seq1	IGHV1-69*02	IGHV1	dezamizumab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGFTFATYNMHWVRQAPGQGLEWMGYIYPGDGNANYNQQFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGDFDYDGGYYFDSWGQGTLVTVSS
site129	DG	N	103	H100	H111A	False	CDR3	H	10364	10364_seq1	IGHV1-69*02	IGHV1	dezamizumab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGFTFATYNMHWVRQAPGQGLEWMGYIYPGDGNANYNQQFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGDFDYDGGYYFDSWGQGTLVTVSS
site130	DG	N+1	104	H100A	H112A	False	CDR3	H	10364	10364_seq1	IGHV1-69*02	IGHV1	dezamizumab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGFTFATYNMHWVRQAPGQGLEWMGYIYPGDGNANYNQQFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGDFDYDGGYYFDSWGQGTLVTVSS
site131	NG	N	32	L28	L34	False	CDR1	K	9754	9754_seq2	IGKV2D-29*02	IGKV2D	dinutuximab	Chimeric	EIVMTQSPATLSVSPGERATLSCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK
site132	NG	N+1	33	L29	L35	True	CDR1	K	9754	9754_seq2	IGKV2D-29*02	IGKV2D	dinutuximab	Chimeric	EIVMTQSPATLSVSPGERATLSCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK
site133	NG	N	32	L28	L34	False	CDR1	K	10137	10137_seq2	IGKV2D-29*02	IGKV2D	dinutuximab beta	Chimeric	EIVMTQSPATLSVSPGERATLSCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK
site134	NG	N+1	33	L29	L35	True	CDR1	K	10137	10137_seq2	IGKV2D-29*02	IGKV2D	dinutuximab beta	Chimeric	EIVMTQSPATLSVSPGERATLSCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK
site135	DG	N	53	H54	H59	False	CDR2	H	11198	11198_seq1	IGHV4-59*11	IGHV4	docaravimab	Mouse	QVQLKESGPGLLAPSQSLSITCTVSGFSLTGHGVNWVRQPPGKGLEWLGIIWADGTTNYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTASYYCAREGDISGYYFDYWGQGTTLTVSS
site136	DG	N+1	54	H55	H63	True	CDR2	H	11198	11198_seq1	IGHV4-59*11	IGHV4	docaravimab	Mouse	QVQLKESGPGLLAPSQSLSITCTVSGFSLTGHGVNWVRQPPGKGLEWLGIIWADGTTNYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTASYYCAREGDISGYYFDYWGQGTTLTVSS
site137	DG	N	53	H53	H59	True	CDR2	H	10010	10010_seq2	IGHV3-7*01	IGHV3	durvalumab	Human	EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSS
site138	DG	N+1	54	H54	H62	True	CDR2	H	10010	10010_seq2	IGHV3-7*01	IGHV3	durvalumab	Human	EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSS
site139	DG	N	98	H95	H107	False	CDR3	H	7471	7471_seq1	IGHV1-2*02	IGHV1	edrecolomab	Mouse	QVQLQQSGAELVRPGTSVKVSCKASGYAFTNYLIEWVKQRPGQGLEWIGVINPGSGGTNYNEKFKGKATLTADKSSSTAYMQLSSLTSDDSAVYFCARDGPWFAYWGQGTLVTVSA
site140	DG	N+1	99	H96	H108	False	CDR3	H	7471	7471_seq1	IGHV1-2*02	IGHV1	edrecolomab	Mouse	QVQLQQSGAELVRPGTSVKVSCKASGYAFTNYLIEWVKQRPGQGLEWIGVINPGSGGTNYNEKFKGKATLTADKSSSTAYMQLSSLTSDDSAVYFCARDGPWFAYWGQGTLVTVSA
site141	NG	N	31	H32	H37	False	CDR1	H	9746	9746_seq1	IGHV3-33*01	IGHV3	eldelumab	Human	QMQLVESGGGVVQPGRSLRLSCTASGFTFSNNGMHWVRQAPGKGLEWVAVIWFDGMNKFYVDSVKGRFTISRDNSKNTLYLEMNSLRAEDTAIYYCAREGDGSGIYYYYGMDVWGQGTTVTVSS
site142	NG	N+1	32	H33	H38	True	CDR1	H	9746	9746_seq1	IGHV3-33*01	IGHV3	eldelumab	Human	QMQLVESGGGVVQPGRSLRLSCTASGFTFSNNGMHWVRQAPGKGLEWVAVIWFDGMNKFYVDSVKGRFTISRDNSKNTLYLEMNSLRAEDTAIYYCAREGDGSGIYYYYGMDVWGQGTTVTVSS
site143	DG	N	53	H53	H59	True	CDR2	H	9746	9746_seq1	IGHV3-33*01	IGHV3	eldelumab	Human	QMQLVESGGGVVQPGRSLRLSCTASGFTFSNNGMHWVRQAPGKGLEWVAVIWFDGMNKFYVDSVKGRFTISRDNSKNTLYLEMNSLRAEDTAIYYCAREGDGSGIYYYYGMDVWGQGTTVTVSS
site144	DG	N+1	54	H54	H62	True	CDR2	H	9746	9746_seq1	IGHV3-33*01	IGHV3	eldelumab	Human	QMQLVESGGGVVQPGRSLRLSCTASGFTFSNNGMHWVRQAPGKGLEWVAVIWFDGMNKFYVDSVKGRFTISRDNSKNTLYLEMNSLRAEDTAIYYCAREGDGSGIYYYYGMDVWGQGTTVTVSS
site145	DG	N	100	H97	H109	False	CDR3	H	9746	9746_seq1	IGHV3-33*01	IGHV3	eldelumab	Human	QMQLVESGGGVVQPGRSLRLSCTASGFTFSNNGMHWVRQAPGKGLEWVAVIWFDGMNKFYVDSVKGRFTISRDNSKNTLYLEMNSLRAEDTAIYYCAREGDGSGIYYYYGMDVWGQGTTVTVSS
site146	DG	N+1	101	H98	H110	False	CDR3	H	9746	9746_seq1	IGHV3-33*01	IGHV3	eldelumab	Human	QMQLVESGGGVVQPGRSLRLSCTASGFTFSNNGMHWVRQAPGKGLEWVAVIWFDGMNKFYVDSVKGRFTISRDNSKNTLYLEMNSLRAEDTAIYYCAREGDGSGIYYYYGMDVWGQGTTVTVSS
site147	DG	N	99	H96	H108	False	CDR3	H	9074	9074_seq1	IGHV3-48*01	IGHV3	elotuzumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSS
site148	DG	N+1	100	H97	H109	False	CDR3	H	9074	9074_seq1	IGHV3-48*01	IGHV3	elotuzumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSS
site149	DG	N	53	H54	H59	False	CDR2	H	9951	9951_seq2	IGHV1-18*01	IGHV1	emactuzumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWMGVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDQRLYFDVWGQGTTVTVSS
site150	DG	N+1	54	H55	H63	True	CDR2	H	9951	9951_seq2	IGHV1-18*01	IGHV1	emactuzumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWMGVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDQRLYFDVWGQGTTVTVSS
site151	DG	N	94	L92	L108	True	CDR3	L	10319	10319_seq1	IGLV6-57*01	IGLV6	emapalumab	Human	NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDGSNRWMFGGGTKLTVL
site152	DG	N+1	95	L93	L109	False	CDR3	L	10319	10319_seq1	IGLV6-57*01	IGLV6	emapalumab	Human	NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDGSNRWMFGGGTKLTVL
site153	DG	N	98	H95	H107	False	CDR3	H	10319	10319_seq2	IGHV3-23*01	IGHV3	emapalumab	Human	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGSSGWYVPHWFDPWGQGTLVTVSS
site154	DG	N+1	99	H96	H108	False	CDR3	H	10319	10319_seq2	IGHV3-23*01	IGHV3	emapalumab	Human	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGSSGWYVPHWFDPWGQGTLVTVSS
site155	DG	N	53	H53	H59	True	CDR2	H	9575	9575_seq2	IGHV3-33*01	IGHV3	enoticumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVSFLWYDGTNKNYVESVKGRFTISRDNSKNMLYLEMNSLRAEDTAVYYCARDHDFRSGYEGWFDPWGQGTLVTVSS
site156	DG	N+1	54	H54	H62	True	CDR2	H	9575	9575_seq2	IGHV3-33*01	IGHV3	enoticumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVSFLWYDGTNKNYVESVKGRFTISRDNSKNMLYLEMNSLRAEDTAVYYCARDHDFRSGYEGWFDPWGQGTLVTVSS
site157	DG	N	53	H54	H59	False	CDR2	H	9300	9300_seq2	IGHV4-4*08	IGHV4	ensituximab	Chimeric	QVQLKESGPDLVAPSQSLSITCTVSGFSLSKFGVNWVRQPPGKGLEWLGVIWGDGSTSYNSGLISRLSISKENSKSQVFLKLNSLQADDTATYYCVKPGGDYWGHGTSVTVSS
site158	DG	N+1	54	H55	H63	True	CDR2	H	9300	9300_seq2	IGHV4-4*08	IGHV4	ensituximab	Chimeric	QVQLKESGPDLVAPSQSLSITCTVSGFSLSKFGVNWVRQPPGKGLEWLGVIWGDGSTSYNSGLISRLSISKENSKSQVFLKLNSLQADDTATYYCVKPGGDYWGHGTSVTVSS
site159	NG	N	53	H54	H59	False	CDR2	H	10308	10308_seq2	IGHV3-66*01	IGHV3	eptinezumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAVSGIDLSGYYMNWVRQAPGKGLEWVGVIGINGATYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVTVSS
site160	NG	N+1	54	H55	H63	True	CDR2	H	10308	10308_seq2	IGHV3-66*01	IGHV3	eptinezumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAVSGIDLSGYYMNWVRQAPGKGLEWVGVIGINGATYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVTVSS
site161	DG	N	53	H54	H59	True	CDR2	H	10296	10296_seq1	IGHV3-30*03	IGHV3	erenumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSIKYSVDSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCARDRLNYYDSSGYYHYKYYGMAVWGQGTTVTVSS
site162	DG	N+1	54	H55	H63	False	CDR2	H	10296	10296_seq1	IGHV3-30*03	IGHV3	erenumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSIKYSVDSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCARDRLNYYDSSGYYHYKYYGMAVWGQGTTVTVSS
site163	DG	N	53	H53	H59	True	CDR2	H	10013	10013_seq2	IGHV3-43*02	IGHV3	evinacumab	Human	EVQLVESGGGVIQPGGSLRLSCAASGFTFDDYAMNWVRQGPGKGLEWVSAISGDGGSTYYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAFFYCAKDLRNTIFGVVIPDAFDIWGQGTMVTVSS
site164	DG	N+1	54	H54	H62	True	CDR2	H	10013	10013_seq2	IGHV3-43*02	IGHV3	evinacumab	Human	EVQLVESGGGVIQPGGSLRLSCAASGFTFDDYAMNWVRQGPGKGLEWVSAISGDGGSTYYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAFFYCAKDLRNTIFGVVIPDAFDIWGQGTMVTVSS
site165	NG	N	54	H54	H62	True	CDR2	H	9643	9643_seq1	IGHV1-18*01	IGHV1	evolocumab	Human	EVQLVQSGAEVKKPGASVKVSCKASGYTLTSYGISWVRQAPGQGLEWMGWVSFYNGNTNYAQKLQGRGTMTTDPSTSTAYMELRSLRSDDTAVYYCARGYGMDVWGQGTTVTVSS
site166	NG	N+1	55	H55	H63	True	CDR2	H	9643	9643_seq1	IGHV1-18*01	IGHV1	evolocumab	Human	EVQLVQSGAEVKKPGASVKVSCKASGYTLTSYGISWVRQAPGQGLEWMGWVSFYNGNTNYAQKLQGRGTMTTDPSTSTAYMELRSLRSDDTAVYYCARGYGMDVWGQGTTVTVSS
site167	DG	N	54	H54	H62	True	CDR2	H	9589	9589_seq2	IGHV1-24*01	IGHV1	fasinumab	Human	QVQLVQSGAEVKKPGASVKVSCKVSGFTLTELSIHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELTSLRSEDTAVYYCSTIFGVVTNFDNWGQGTLVTVSS
site168	DG	N+1	55	H55	H63	True	CDR2	H	9589	9589_seq2	IGHV1-24*01	IGHV1	fasinumab	Human	QVQLVQSGAEVKKPGASVKVSCKVSGFTLTELSIHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELTSLRSEDTAVYYCSTIFGVVTNFDNWGQGTLVTVSS
site169	DG	N	54	H54	H62	False	CDR2	H	11179	11179_seq2	IGHV1-58*01	IGHV1	favezelimab	Humanized	QMQLVQSGPEVKKPGTSVKVSCKASGYTFTDYNVDWVRQARGQRLEWIGDINPNDGGTIYAQKFQERVTITVDKSTSTAYMELSSLRSEDTAVYYCARNYRWFGAMDHWGQGTTVTVSS
site170	DG	N+1	55	H55	H63	True	CDR2	H	11179	11179_seq2	IGHV1-58*01	IGHV1	favezelimab	Humanized	QMQLVQSGPEVKKPGTSVKVSCKASGYTFTDYNVDWVRQARGQRLEWIGDINPNDGGTIYAQKFQERVTITVDKSTSTAYMELSSLRSEDTAVYYCARNYRWFGAMDHWGQGTTVTVSS
site171	DG	N	53	H53	H59	True	CDR2	H	11182	11182_seq2	IGHV3-33*01	IGHV3	fianlimab	Human	QVQLVESGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAIIWYDGSNKYYADSVKGRFTISRDNSKNTQYLQMNSLRAEDTAVYYCASVATSGDFDYYGMDVWGQGTTVTVSS
site172	DG	N+1	54	H54	H62	True	CDR2	H	11182	11182_seq2	IGHV3-33*01	IGHV3	fianlimab	Human	QVQLVESGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAIIWYDGSNKYYADSVKGRFTISRDNSKNTQYLQMNSLRAEDTAVYYCASVATSGDFDYYGMDVWGQGTTVTVSS
site173	NG	N	54	H54	H62	False	CDR2	H	9465	9465_seq1	IGHV1-46*01	IGHV1	ficlatuzumab	Humanized	QVQLVQPGAEVKKPGTSVKLSCKASGYTFTTYWMHWVRQAPGQGLEWIGEINPTNGHTNYNQKFQGRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNYVGSIFDYWGQGTLLTVSS
site174	NG	N+1	55	H55	H63	True	CDR2	H	9465	9465_seq1	IGHV1-46*01	IGHV1	ficlatuzumab	Humanized	QVQLVQPGAEVKKPGTSVKLSCKASGYTFTTYWMHWVRQAPGQGLEWIGEINPTNGHTNYNQKFQGRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNYVGSIFDYWGQGTLLTVSS
site175	DG	N	98	H95	H107	False	CDR3	H	9975	9975_seq2	IGHV1-69*01	IGHV1	firivumab	Human	QVQLVQSGAEVKMPGSSVKVSCKTSGVFFSSHAISWVRQAPGQGLEWMGGISPMFGTTHYAQKFQGRVTITADQSTTTAYMELTSLTSEDTAVYYCARDGAGSYYPLNWFDPWGQGTLVTVSS
site176	DG	N+1	99	H96	H108	False	CDR3	H	9975	9975_seq2	IGHV1-69*01	IGHV1	firivumab	Human	QVQLVQSGAEVKMPGSSVKVSCKTSGVFFSSHAISWVRQAPGQGLEWMGGISPMFGTTHYAQKFQGRVTITADQSTTTAYMELTSLTSEDTAVYYCARDGAGSYYPLNWFDPWGQGTLVTVSS
site177	DG	N	53	H53	H59	True	CDR2	H	9309	9309_seq1	IGHV3-33*01	IGHV3	foralumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFKFSGYGMHWVRQAPGKGLEWVAVIWYDGSKKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQMGYWHFDLWGRGTLVTVSS
site178	DG	N+1	54	H54	H62	True	CDR2	H	9309	9309_seq1	IGHV3-33*01	IGHV3	foralumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFKFSGYGMHWVRQAPGKGLEWVAVIWYDGSKKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQMGYWHFDLWGRGTLVTVSS
site179	DG	N	53	H53	H59	True	CDR2	H	9053	9053_seq1	IGHV3-30*18	IGHV3	foravirumab	Human	QVQLVESGGGAVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVILYDGSDKFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVAVAGTHFDYWGQGTLVTVSS
site180	DG	N+1	54	H54	H62	True	CDR2	H	9053	9053_seq1	IGHV3-30*18	IGHV3	foravirumab	Human	QVQLVESGGGAVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVILYDGSDKFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVAVAGTHFDYWGQGTLVTVSS
site181	NG	N	32	L28	L34	True	CDR1	K	10859	10859_seq1	IGKV2-28*01	IGKV2	frovocimab	Humanized	DIVMTQSPLSLPVTPGEPASISCRSSKSLLHRNGITYSYWYLQKPGQSPQLLIYQLSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCYQNLELPLTFGQGTKVEIK
site182	NG	N+1	33	L29	L35	True	CDR1	K	10859	10859_seq1	IGKV2-28*01	IGKV2	frovocimab	Humanized	DIVMTQSPLSLPVTPGEPASISCRSSKSLLHRNGITYSYWYLQKPGQSPQLLIYQLSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCYQNLELPLTFGQGTKVEIK
site183	NG	N	98	H95	H107	False	CDR3	H	9612	9612_seq1	IGHV1-46*01	IGHV1	futuximab	Chimeric	EVQLQQPGSELVRPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGNIYPGSRSTNYDEKFKSKATLTVDTSSSTAYMQLSSLTSEDSAVYYCTRNGDYYVSSGDAMDYWGQGTSVTVSS
site184	NG	N+1	99	H96	H108	False	CDR3	H	9612	9612_seq1	IGHV1-46*01	IGHV1	futuximab	Chimeric	EVQLQQPGSELVRPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGNIYPGSRSTNYDEKFKSKATLTVDTSSSTAYMQLSSLTSEDSAVYYCTRNGDYYVSSGDAMDYWGQGTSVTVSS
site185	NG	N	32	L28	L34	True	CDR1	K	9323	9323_seq2	IGKV2-28*01	IGKV2	ganitumab	Human	DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGQGTKVEIK
site186	NG	N+1	33	L29	L35	True	CDR1	K	9323	9323_seq2	IGKV2-28*01	IGKV2	ganitumab	Human	DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGQGTKVEIK
site187	NG	N	32	L28	L34	True	CDR1	K	10336	10336_seq1	IGKV2-28*01	IGKV2	gatipotuzumab	Humanized	DIVMTQSPLSNPVTPGEPASISCRSSKSLLHSNGITYFFWYLQKPGQSPQLLIYQMSNLASGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGQGTKVEIK
site188	NG	N+1	33	L29	L35	True	CDR1	K	10336	10336_seq1	IGKV2-28*01	IGKV2	gatipotuzumab	Humanized	DIVMTQSPLSNPVTPGEPASISCRSSKSLLHSNGITYFFWYLQKPGQSPQLLIYQMSNLASGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGQGTKVEIK
site189	NG	N	32	L28	L34	False	CDR1	K	11046	11046_seq1	IGKV2-29*02	IGKV2	gatralimab	Humanized/Chimeric	DIVMTQTPLSLSVTPGQPASISCKSSQSLLYSNGKTYLNWVLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCVQGSHFHTFGQGTKLEIK
site190	NG	N+1	33	L29	L35	True	CDR1	K	11046	11046_seq1	IGKV2-29*02	IGKV2	gatralimab	Humanized/Chimeric	DIVMTQTPLSLSVTPGQPASISCKSSQSLLYSNGKTYLNWVLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCVQGSHFHTFGQGTKLEIK
site191	DG	N	53	H53	H59	True	CDR2	H	10459	10459_seq1	IGHV3-30*01	IGHV3	gedivumab	Human	EVQLVESGGGVVQPGKSLRLSCAASGLTFSSYAVHWVRQAPGKGLEWVTLISYDGANQYYADSVKGRFTISRDNSKNTVYLQMNSLRPEDTAVYYCAVPGPVFGIFPPWSYFDNWGQGILVTVSS
site192	DG	N+1	54	H54	H62	True	CDR2	H	10459	10459_seq1	IGHV3-30*01	IGHV3	gedivumab	Human	EVQLVESGGGVVQPGKSLRLSCAASGLTFSSYAVHWVRQAPGKGLEWVTLISYDGANQYYADSVKGRFTISRDNSKNTVYLQMNSLRPEDTAVYYCAVPGPVFGIFPPWSYFDNWGQGILVTVSS
site193	NG	N	54	H54	H62	True	CDR2	H	10315	10315_seq1	IGHV1-3*01	IGHV1	gemtuzumab ozogamicin	Humanized	EVQLVQSGAEVKKPGSSVKVSCKASGYTITDSNIHWVRQAPGQSLEWIGYIYPYNGGTDYNQKFKNRATLTVDNPTNTAYMELSSLRSEDTAFYYCVNGNPWLAYWGQGTLVTVSS
site194	NG	N+1	55	H55	H63	True	CDR2	H	10315	10315_seq1	IGHV1-3*01	IGHV1	gemtuzumab ozogamicin	Humanized	EVQLVQSGAEVKKPGSSVKVSCKASGYTITDSNIHWVRQAPGQSLEWIGYIYPYNGGTDYNQKFKNRATLTVDNPTNTAYMELSSLRSEDTAFYYCVNGNPWLAYWGQGTLVTVSS
site195	DG	N	55	H54	H59	False	CDR2	H	9310	9310_seq1	IGHV4-38-2*01	IGHV4	gevokizumab	Humanized	QVQLQESGPGLVKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDGDESYNPSLKSRLTISKDTSKNQVSLKITSVTAADTAVYFCARNRYDPPWFVDWGQGTLVTVSS
site196	DG	N+1	56	H55	H63	True	CDR2	H	9310	9310_seq1	IGHV4-38-2*01	IGHV4	gevokizumab	Humanized	QVQLQESGPGLVKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDGDESYNPSLKSRLTISKDTSKNQVSLKITSVTAADTAVYFCARNRYDPPWFVDWGQGTLVTVSS
site197	DG	N	54	H54	H59	False	CDR2	H	11241	11241_seq1	IGHV4-59*01	IGHV4	giloralimab	Humanized/Chimeric	EVQLQESGPGLVKPSETLSLTCTVSGYSITSNYYWNWIRQPPGKGLEWMGYIRYDGSNNYNPSLKNRVTISRDTSKNQFSLKLSSVTAADTAVYYCARLDYWGQGTTVTVSS
site198	DG	N+1	55	H55	H63	True	CDR2	H	11241	11241_seq1	IGHV4-59*01	IGHV4	giloralimab	Humanized/Chimeric	EVQLQESGPGLVKPSETLSLTCTVSGYSITSNYYWNWIRQPPGKGLEWMGYIRYDGSNNYNPSLKNRVTISRDTSKNQFSLKLSSVTAADTAVYYCARLDYWGQGTTVTVSS
site199	NG	N	32	L28	L34	False	CDR1	K	11241	11241_seq2	IGKV2-29*02	IGKV2	giloralimab	Humanized/Chimeric	DIVMTQTPLSLSVTPGQPASISCRSSQSLENTNGNTFLNWYLQKPGQSPQLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQVTHVPFTFGQGTKLEIK
site200	NG	N+1	33	L29	L35	True	CDR1	K	11241	11241_seq2	IGKV2-29*02	IGKV2	giloralimab	Humanized/Chimeric	DIVMTQTPLSLSVTPGQPASISCRSSQSLENTNGNTFLNWYLQKPGQSPQLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQVTHVPFTFGQGTKLEIK
site201	NG	N	51	H52	H57	True	CDR2	H	10534	10534_seq1	IGHV3-74*03	IGHV3	gimsilumab	Human	EVQLVESGGGLVQPGGSLRLSCAASGFTFSRHWMHWLRQVPGKGPVWVSRINGAGTSITYADSVRGRFTISRDNANNTLFLQMNSLRADDTALYFCARANSVWFRGLFDYWGQGTPVTVSS
site202	NG	N+1	52	H52A	H58	False	CDR2	H	10534	10534_seq1	IGHV3-74*03	IGHV3	gimsilumab	Human	EVQLVESGGGLVQPGGSLRLSCAASGFTFSRHWMHWLRQVPGKGPVWVSRINGAGTSITYADSVRGRFTISRDNANNTLFLQMNSLRADDTALYFCARANSVWFRGLFDYWGQGTPVTVSS
site203	DG	N	53	H53	H59	False	CDR2	H	9116	9116_seq2	IGHV3-11*01	IGHV3	girentuximab	Chimeric	DVKLVESGGGLVKLGGSLKLSCAASGFTFSNYYMSWVRQTPEKRLELVAAINSDGGITYYLDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALFYCARHRSGYFSMDYWGQGTSVTVSS
site204	DG	N+1	54	H54	H62	True	CDR2	H	9116	9116_seq2	IGHV3-11*01	IGHV3	girentuximab	Chimeric	DVKLVESGGGLVKLGGSLKLSCAASGFTFSNYYMSWVRQTPEKRLELVAAINSDGGITYYLDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALFYCARHRSGYFSMDYWGQGTSVTVSS
site205	NG	N	32	L28	L34	False	CDR1	K	10956	10956_seq1	IGKV1-33*01	IGKV1	glenzocimab	Humanized	DIQMTQSPSSLSASVGDRVTITCRSSQSLENSNGNTYLNWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQLTHVPWTFGQGTKVEIT
site206	NG	N+1	33	L29	L35	False	CDR1	K	10956	10956_seq1	IGKV1-33*01	IGKV1	glenzocimab	Humanized	DIQMTQSPSSLSASVGDRVTITCRSSQSLENSNGNTYLNWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQLTHVPWTFGQGTKVEIT
site207	NG	N	54	H54	H62	False	CDR2	H	10956	10956_seq2	IGHV1-46*01	IGHV1	glenzocimab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGGIYPGNGDTSYNQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGTVVGDWYFDVWGQGTLVTVSS
site208	NG	N+1	55	H55	H63	True	CDR2	H	10956	10956_seq2	IGHV1-46*01	IGHV1	glenzocimab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGGIYPGNGDTSYNQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGTVVGDWYFDVWGQGTLVTVSS
site209	NG	N	60	H60	H68	False	CDR2	H	11145	11145_seq1	IGHV1-69*02	IGHV1	glofitamab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS
site210	NG	N+1	61	H61	H69	False	CDR2	H	11145	11145_seq1	IGHV1-69*02	IGHV1	glofitamab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS
site211	DG	N	54	H54	H62	False	CDR2	H	11145	11145_seq1	IGHV1-69*02	IGHV1	glofitamab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS
site212	DG	N+1	55	H55	H63	True	CDR2	H	11145	11145_seq1	IGHV1-69*02	IGHV1	glofitamab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS
site213	DG	N	101	H98	H110	False	CDR3	H	11145	11145_seq1	IGHV1-69*02	IGHV1	glofitamab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS
site214	DG	N+1	102	H99	H112	False	CDR3	H	11145	11145_seq1	IGHV1-69*02	IGHV1	glofitamab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS
site215	NG	N	32	L28	L34	True	CDR1	K	11145	11145_seq3	IGKV2-28*01	IGKV2	glofitamab	Humanized	DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK
site216	NG	N+1	33	L29	L35	True	CDR1	K	11145	11145_seq3	IGKV2-28*01	IGKV2	glofitamab	Humanized	DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK
site217	DG	N	100	H97	H109	False	CDR3	H	10663	10663_seq1	IGHV3-11*01	IGHV3	gosuranemab	Chimeric	EVHLVESGGALVKPGGSLRLSCAASGFSFSKYGMSWVRQAPGKGLEWVATISSSGSRTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCSISWDGAMDYWGQGTTVTVSS
site218	DG	N+1	101	H98	H113	False	CDR3	H	10663	10663_seq1	IGHV3-11*01	IGHV3	gosuranemab	Chimeric	EVHLVESGGALVKPGGSLRLSCAASGFSFSKYGMSWVRQAPGKGLEWVATISSSGSRTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCSISWDGAMDYWGQGTTVTVSS
site219	NG	N	32	L28	L34	False	CDR1	K	10663	10663_seq2	IGKV2-30*02	IGKV2	gosuranemab	Chimeric	DVVMTQSPLSLPVTLGQPASISCKSSQSIVHSNGNTYLEWYLQKPGQSPQLLVYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGTYYCFQGSLVPWAFGGGTKVEIK
site220	NG	N+1	33	L29	L35	True	CDR1	K	10663	10663_seq2	IGKV2-30*02	IGKV2	gosuranemab	Chimeric	DVVMTQSPLSLPVTLGQPASISCKSSQSIVHSNGNTYLEWYLQKPGQSPQLLVYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGTYYCFQGSLVPWAFGGGTKVEIK
site221	DG	N	94	L93	L109	False	CDR3	L	9774	9774_seq1	IGLV1-40*01	IGLV1	guselkumab	Human	QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVL
site222	DG	N+1	95	L94	L110	False	CDR3	L	9774	9774_seq1	IGLV1-40*01	IGLV1	guselkumab	Human	QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVL
site223	DG	N	55	H55	H63	False	CDR2	H	8818	8818_seq1	IGHV1-46*01	IGHV1	ibalizumab	Humanized	QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSS
site224	DG	N+1	56	H56	H64	False	CDR2	H	8818	8818_seq1	IGHV1-46*01	IGHV1	ibalizumab	Humanized	QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSS
site225	DG	N	32	L28	L34	True	CDR1	K	11192	11192_seq1	IGKV2-30*01	IGKV2	icatolimab	Chimeric	DVVMTQTPLSLSVTPGQPASISCKSSQSLLDSDGKTYLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTYFPYTFGQGTKLEIK
site226	DG	N+1	33	L29	L35	True	CDR1	K	11192	11192_seq1	IGKV2-30*01	IGKV2	icatolimab	Chimeric	DVVMTQTPLSLSVTPGQPASISCKSSQSLLDSDGKTYLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTYFPYTFGQGTKLEIK
site227	NG	N	54	H54	H62	False	CDR2	H	11192	11192_seq2	IGHV1-2*06	IGHV1	icatolimab	Chimeric	QVQLVQSGAEVKKPGASVKLSCKASGYNFKHTYAHWVRQAPGQGLEWIGRIDPANGNTKYDPKFQGRATMTADTASNTAYLELSSLRSEDTAVYYCVADHYGSSLLDYWGQGTLVTVSS
site228	NG	N+1	55	H55	H63	True	CDR2	H	11192	11192_seq2	IGHV1-2*06	IGHV1	icatolimab	Chimeric	QVQLVQSGAEVKKPGASVKLSCKASGYNFKHTYAHWVRQAPGQGLEWIGRIDPANGNTKYDPKFQGRATMTADTASNTAYLELSSLRSEDTAVYYCVADHYGSSLLDYWGQGTLVTVSS
site229	DG	N	53	H53	H59	True	CDR2	H	9370	9370_seq2	IGHV3-33*01	IGHV3	icrucumab	Human	QAQVVESGGGVVQSGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVRGRFTISRDNSENTLYLQMNSLRAEDTAVYYCARDHYGSGVHHYFYYGLDVWGQGTTVTVSS
site230	DG	N+1	54	H54	H62	True	CDR2	H	9370	9370_seq2	IGHV3-33*01	IGHV3	icrucumab	Human	QAQVVESGGGVVQSGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVRGRFTISRDNSENTLYLQMNSLRAEDTAVYYCARDHYGSGVHHYFYYGLDVWGQGTTVTVSS
site231	DG	N	106	H100D	H113	False	CDR3	H	9698	9698_seq1	IGHV4-4*08	IGHV4	idarucizumab	Humanized	QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYIVDWIRQPPGKGLEWIGVIWAGGSTGYNSALRSRVSITKDTSKNQFSLKLSSVTAADTAVYYCASAAYYSYYNYDGFAYWGQGTLVTVSS
site232	DG	N+1	107	H100E	H114	False	CDR3	H	9698	9698_seq1	IGHV4-4*08	IGHV4	idarucizumab	Humanized	QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYIVDWIRQPPGKGLEWIGVIWAGGSTGYNSALRSRVSITKDTSKNQFSLKLSSVTAADTAVYYCASAAYYSYYNYDGFAYWGQGTLVTVSS
site233	DG	N	32	L28	L34	True	CDR1	K	9698	9698_seq2	IGKV2-30*01	IGKV2	idarucizumab	Humanized	DVVMTQSPLSLPVTLGQPASISCKSSQSLLYTDGKTYLYWFLQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQSTHFPHTFGGGTKVEIK
site234	DG	N+1	33	L29	L35	True	CDR1	K	9698	9698_seq2	IGKV2-30*01	IGKV2	idarucizumab	Humanized	DVVMTQSPLSLPVTLGQPASISCKSSQSLLYTDGKTYLYWFLQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQSTHFPHTFGGGTKVEIK
site235	DG	N	53	H53	H59	True	CDR2	H	11863	11863_seq2	IGHV3-30*01	IGHV3	imdevimab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMYWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRTEDTAVYYCASGSDYGDYLLVYWGQGTLVTVSS
site236	DG	N+1	54	H54	H62	True	CDR2	H	11863	11863_seq2	IGHV3-30*01	IGHV3	imdevimab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMYWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRTEDTAVYYCASGSDYGDYLLVYWGQGTLVTVSS
site237	DG	N	54	H54	H62	False	CDR2	H	9985	9985_seq2	IGHV3-15*06	IGHV3	inebilizumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSSWMNWVRQAPGKGLEWVGRIYPGDGDTNYNVKFKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARSGFITTVRDFDYWGQGTLVTVSS
site238	DG	N+1	55	H55	H63	True	CDR2	H	9985	9985_seq2	IGHV3-15*06	IGHV3	inebilizumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSSWMNWVRQAPGKGLEWVGRIYPGDGDTNYNVKFKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARSGFITTVRDFDYWGQGTLVTVSS
site239	DG	N	53	H53	H59	True	CDR2	H	9134	9134_seq1	IGHV3-30*01	IGHV3	intetumumab	Human	QVQLVESGGGVVQPGRSRRLSCAASGFTFSRYTMHWVRQAPGKGLEWVAVISFDGSNKYYVDSVKGRFTISRDNSENTLYLQVNILRAEDTAVYYCAREARGSYAFDIWGQGTMVTVSS
site240	DG	N+1	54	H54	H62	True	CDR2	H	9134	9134_seq1	IGHV3-30*01	IGHV3	intetumumab	Human	QVQLVESGGGVVQPGRSRRLSCAASGFTFSRYTMHWVRQAPGKGLEWVAVISFDGSNKYYVDSVKGRFTISRDNSENTLYLQVNILRAEDTAVYYCAREARGSYAFDIWGQGTMVTVSS
site241	DG	N	53	H53	H59	False	CDR2	H	9117	9117_seq2	IGHV3-11*01	IGHV3	iodine (124I) girentuximab	Chimeric	DVKLVESGGGLVKLGGSLKLSCAASGFTFSNYYMSWVRQTPEKRLELVAAINSDGGITYYLDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALFYCARHRSGYFSMDYWGQGTSVTVSS
site242	DG	N+1	54	H54	H62	True	CDR2	H	9117	9117_seq2	IGHV3-11*01	IGHV3	iodine (124I) girentuximab	Chimeric	DVKLVESGGGLVKLGGSLKLSCAASGFTFSNYYMSWVRQTPEKRLELVAAINSDGGITYYLDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALFYCARHRSGYFSMDYWGQGTSVTVSS
site243	DG	N	53	H53	H59	True	CDR2	H	8568	8568_seq2	IGHV3-30*01	IGHV3	ipilimumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS
site244	DG	N+1	54	H54	H62	True	CDR2	H	8568	8568_seq2	IGHV3-30*01	IGHV3	ipilimumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS
site245	DG	N	54	H54	H62	False	CDR2	H	10068	10068_seq2	IGHV1-46*01	IGHV1	isatuximab	Chimeric	QVQLVQSGAEVAKPGTSVKLSCKASGYTFTDYWMQWVKQRPGQGLEWIGTIYPGDGDTGYAQKFQGKATLTADKSSKTVYMHLSSLASEDSAVYYCARGDYYGSNSLDYWGQGTSVTVSS
site246	DG	N+1	55	H55	H63	True	CDR2	H	10068	10068_seq2	IGHV1-46*01	IGHV1	isatuximab	Chimeric	QVQLVQSGAEVAKPGTSVKLSCKASGYTFTDYWMQWVKQRPGQGLEWIGTIYPGDGDTGYAQKFQGKATLTADKSSKTVYMHLSSLASEDSAVYYCARGDYYGSNSLDYWGQGTSVTVSS
site247	NG	N	32	L28	L34	True	CDR1	K	10707	10707_seq1	IGKV2-28*01	IGKV2	iscalimab	Human	DIVMTQSPLSLTVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQVLISLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPFTFGPGTKVDIR
site248	NG	N+1	33	L29	L35	True	CDR1	K	10707	10707_seq1	IGKV2-28*01	IGKV2	iscalimab	Human	DIVMTQSPLSLTVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQVLISLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPFTFGPGTKVDIR
site249	DG	N	98	H95	H107	False	CDR3	H	10707	10707_seq2	IGHV3-30*03	IGHV3	iscalimab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYEESNRYHADSVKGRFTISRDNSKITLYLQMNSLRTEDTAVYYCARDGGIAAPGPDYWGQGTLVTVSS
site250	DG	N+1	99	H96	H108	False	CDR3	H	10707	10707_seq2	IGHV3-30*03	IGHV3	iscalimab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYEESNRYHADSVKGRFTISRDNSKITLYLQMNSLRTEDTAVYYCARDGGIAAPGPDYWGQGTLVTVSS
site251	NG	N	54	H54	H62	False	CDR2	H	10630	10630_seq2	IGHV1-2*02	IGHV1	ladiratuzumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGLTIEDYYMHWVRQAPGQGLEWMGWIDPENGDTEYGPKFQGRVTMTRDTSINTAYMELSRLRSDDTAVYYCAVHNAHYGTWFAYWGQGTLVTVSS
site252	NG	N+1	55	H55	H63	True	CDR2	H	10630	10630_seq2	IGHV1-2*02	IGHV1	ladiratuzumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGLTIEDYYMHWVRQAPGQGLEWMGWIDPENGDTEYGPKFQGRVTMTRDTSINTAYMELSRLRSDDTAVYYCAVHNAHYGTWFAYWGQGTLVTVSS
site253	NG	N	54	H54	H62	False	CDR2	H	10625	10625_seq2	IGHV1-2*02	IGHV1	ladiratuzumab vedotin	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGLTIEDYYMHWVRQAPGQGLEWMGWIDPENGDTEYGPKFQGRVTMTRDTSINTAYMELSRLRSDDTAVYYCAVHNAHYGTWFAYWGQGTLVTVSS
site254	NG	N+1	55	H55	H63	True	CDR2	H	10625	10625_seq2	IGHV1-2*02	IGHV1	ladiratuzumab vedotin	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGLTIEDYYMHWVRQAPGQGLEWMGWIDPENGDTEYGPKFQGRVTMTRDTSINTAYMELSRLRSDDTAVYYCAVHNAHYGTWFAYWGQGTLVTVSS
site255	DG	N	54	H54	H62	False	CDR2	H	10237	10237_seq1	IGHV1-3*01	IGHV1	laprituximab	Chimeric	QVQLVQSGAEVAKPGASVKLSCKASGYTFTSYWMQWVKQRPGQGLECIGTIYPGDGDTTYTQKFQGKATLTADKSSSTAYMQLSSLRSEDSAVYYCARYDAPGYAMDYWGQGTLVTVSS
site256	DG	N+1	55	H55	H63	True	CDR2	H	10237	10237_seq1	IGHV1-3*01	IGHV1	laprituximab	Chimeric	QVQLVQSGAEVAKPGASVKLSCKASGYTFTSYWMQWVKQRPGQGLECIGTIYPGDGDTTYTQKFQGKATLTADKSSSTAYMQLSSLRSEDSAVYYCARYDAPGYAMDYWGQGTLVTVSS
site257	DG	N	54	H54	H62	False	CDR2	H	10236	10236_seq1	IGHV1-3*01	IGHV1	laprituximab emtansine	Chimeric	QVQLVQSGAEVAKPGASVKLSCKASGYTFTSYWMQWVKQRPGQGLECIGTIYPGDGDTTYTQKFQGKATLTADKSSSTAYMQLSSLRSEDSAVYYCARYDAPGYAMDYWGQGTLVTVSS
site258	DG	N+1	55	H55	H63	True	CDR2	H	10236	10236_seq1	IGHV1-3*01	IGHV1	laprituximab emtansine	Chimeric	QVQLVQSGAEVAKPGASVKLSCKASGYTFTSYWMQWVKQRPGQGLECIGTIYPGDGDTTYTQKFQGKATLTADKSSSTAYMQLSSLRSEDSAVYYCARYDAPGYAMDYWGQGTLVTVSS
site259	DG	N	53	H54	H59	True	CDR2	H	9165	9165_seq2	IGHV2-70*01	IGHV2	lebrikizumab	Humanized	QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSS
site260	DG	N+1	54	H55	H63	False	CDR2	H	9165	9165_seq2	IGHV2-70*01	IGHV2	lebrikizumab	Humanized	QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSS
site261	DG	N	97	H95	H107	False	CDR3	H	9165	9165_seq2	IGHV2-70*01	IGHV2	lebrikizumab	Humanized	QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSS
site262	DG	N+1	98	H96	H108	False	CDR3	H	9165	9165_seq2	IGHV2-70*01	IGHV2	lebrikizumab	Humanized	QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSS
site263	NG	N	32	L28	L34	False	CDR1	K	11194	11194_seq2	IGKV2-30*02	IGKV2	lecanemab	Humanized/Chimeric	DVVMTQSPLSLPVTPGAPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLRISRVEAEDVGIYYCFQGSHVPPTFGPGTKLEIK
site264	NG	N+1	33	L29	L35	True	CDR1	K	11194	11194_seq2	IGKV2-30*02	IGKV2	lecanemab	Humanized/Chimeric	DVVMTQSPLSLPVTPGAPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLRISRVEAEDVGIYYCFQGSHVPPTFGPGTKLEIK
site265	DG	N	98	H95	H107	False	CDR3	H	10746	10746_seq1	IGHV3-21*01	IGHV3	lenvervimab	Humanized	EVQLVESGGGLVKPGGSLRLSCSASGFSLTKYKMTWVRQAPGKGLEWVSSISSTSRDIDYADSVKGRFTISRDNAKNSLFLQMSSLRVDDTAVYYCTRDGWLWGWDVRSNYYYNALDVWGQGTTVTVSS
site266	DG	N+1	99	H96	H108	False	CDR3	H	10746	10746_seq1	IGHV3-21*01	IGHV3	lenvervimab	Humanized	EVQLVESGGGLVKPGGSLRLSCSASGFSLTKYKMTWVRQAPGKGLEWVSSISSTSRDIDYADSVKGRFTISRDNAKNSLFLQMSSLRVDDTAVYYCTRDGWLWGWDVRSNYYYNALDVWGQGTTVTVSS
site267	NG	N	54	H54	H62	True	CDR2	H	9965	9965_seq1	IGHV1-3*01	IGHV1	lenzilumab	Human	QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCVRRQRFPYYFDYWGQGTLVTVSS
site268	NG	N+1	55	H55	H63	True	CDR2	H	9965	9965_seq1	IGHV1-3*01	IGHV1	lenzilumab	Human	QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCVRRQRFPYYFDYWGQGTLVTVSS
site269	NG	N	32	L28	L34	True	CDR1	K	10458	10458_seq2	IGKV2-28*01	IGKV2	lesofavumab	Human	DIVMTQSPLSLPVTPGEPASISCRSSQSLLRSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKLEIK
site270	NG	N+1	33	L29	L35	True	CDR1	K	10458	10458_seq2	IGKV2-28*01	IGKV2	lesofavumab	Human	DIVMTQSPLSLPVTPGEPASISCRSSQSLLRSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKLEIK
site271	DG	N	53	H54	H59	False	CDR2	H	10905	10905_seq2	IGHV3-66*01	IGHV3	levilimab	Humanized/Chimeric	QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIYSDGTTHYGDSVKGRFTISRDNAKNTVYLQLNSLRAEDTAMYYCAKGAGPTWWYALDAWGQGTLVTVSS
site272	DG	N+1	54	H55	H63	True	CDR2	H	10905	10905_seq2	IGHV3-66*01	IGHV3	levilimab	Humanized/Chimeric	QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIYSDGTTHYGDSVKGRFTISRDNAKNTVYLQLNSLRAEDTAMYYCAKGAGPTWWYALDAWGQGTLVTVSS
site273	NG	N	53	H53	H59	True	CDR2	H	8753	8753_seq2	IGHV3-20*04	IGHV3	lexatumumab	Human	EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDLWGKGTTVTVSS
site274	NG	N+1	54	H54	H62	True	CDR2	H	8753	8753_seq2	IGHV3-20*04	IGHV3	lexatumumab	Human	EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDLWGKGTTVTVSS
site275	NG	N	54	H54	H62	True	CDR2	H	10071	10071_seq1	IGHV1-3*01	IGHV1	lilotomab	Mouse	EIQLQQSGPELVKPGASVKVSCKASGYSFTDYNMYWVKQSHGKSLEWIGYIDPYNGDTTYNQKFKGKATLTVDKSSSTAFIHLNSLTSEDSAVYYCARSPYGHYAMDYWGQGTSVTVSS
site276	NG	N+1	55	H55	H63	True	CDR2	H	10071	10071_seq1	IGHV1-3*01	IGHV1	lilotomab	Mouse	EIQLQQSGPELVKPGASVKVSCKASGYSFTDYNMYWVKQSHGKSLEWIGYIDPYNGDTTYNQKFKGKATLTVDKSSSTAFIHLNSLTSEDSAVYYCARSPYGHYAMDYWGQGTSVTVSS
site277	NG	N	32	L28	L34	False	CDR1	K	10954	10954_seq2	IGKV2-30*02	IGKV2	lorukafusp alfa	Chimeric	DVVMTQTPLSLPVTPGEPASISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK
site278	NG	N+1	33	L29	L35	True	CDR1	K	10954	10954_seq2	IGKV2-30*02	IGKV2	lorukafusp alfa	Chimeric	DVVMTQTPLSLPVTPGEPASISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK
site279	DG	N	32	L28	L34	True	CDR1	K	9299	9299_seq2	IGKV2-30*02	IGKV2	lorvotuzumab mertansine	Humanized	DVVMTQSPLSLPVTLGQPASISCRSSQIIIHSDGNTYLEWFQQRPGQSPRRLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPHTFGQGTKVEIK
site280	DG	N+1	33	L29	L35	True	CDR1	K	9299	9299_seq2	IGKV2-30*02	IGKV2	lorvotuzumab mertansine	Humanized	DVVMTQSPLSLPVTLGQPASISCRSSQIIIHSDGNTYLEWFQQRPGQSPRRLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPHTFGQGTKVEIK
site281	NG	N	54	H54	H59	False	CDR2	H	10409	10409_seq1	IGHV4-30-4*01	IGHV4	losatuxizumab	Humanized/Chimeric	EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS
site282	NG	N+1	55	H55	H63	True	CDR2	H	10409	10409_seq1	IGHV4-30-4*01	IGHV4	losatuxizumab	Humanized/Chimeric	EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS
site283	NG	N	54	H54	H59	False	CDR2	H	10342	10342_seq1	IGHV4-30-4*01	IGHV4	losatuxizumab vedotin	Humanized/Chimeric	EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS
site284	NG	N+1	55	H55	H63	True	CDR2	H	10342	10342_seq1	IGHV4-30-4*01	IGHV4	losatuxizumab vedotin	Humanized/Chimeric	EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS
site285	DG	N	98	H95	H107	False	CDR3	H	8887	8887_seq1	IGHV3-30*03	IGHV3	lucatumumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYEESNRYHADSVKGRFTISRDNSKITLYLQMNSLRTEDTAVYYCARDGGIAAPGPDYWGQGTLVTVSS
site286	DG	N+1	99	H96	H108	False	CDR3	H	8887	8887_seq1	IGHV3-30*03	IGHV3	lucatumumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYEESNRYHADSVKGRFTISRDNSKITLYLQMNSLRTEDTAVYYCARDGGIAAPGPDYWGQGTLVTVSS
site287	NG	N	32	L28	L34	True	CDR1	K	8887	8887_seq2	IGKV2-28*01	IGKV2	lucatumumab	Human	DIVMTQSPLSLTVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQVLISLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPFTFGPGTKVDIR
site288	NG	N+1	33	L29	L35	True	CDR1	K	8887	8887_seq2	IGKV2-28*01	IGKV2	lucatumumab	Human	DIVMTQSPLSLTVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQVLISLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPFTFGPGTKVDIR
site289	NG	N	97	L95A	L114	False	CDR3	L	10258	10258_seq2	IGLV1-50*01	IGLV1	lupartumab	Human	ESVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYVVHWYQQLPGTAPKLLIYDNNKRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDRLNGPVFGGGTKLTVL
site290	NG	N+1	98	L95B	L115	False	CDR3	L	10258	10258_seq2	IGLV1-50*01	IGLV1	lupartumab	Human	ESVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYVVHWYQQLPGTAPKLLIYDNNKRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDRLNGPVFGGGTKLTVL
site291	NG	N	97	L95A	L114	False	CDR3	L	10257	10257_seq2	IGLV1-50*01	IGLV1	lupartumab amadotin	Human	ESVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYVVHWYQQLPGTAPKLLIYDNNKRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDRLNGPVFGGGTKLTVL
site292	NG	N+1	98	L95B	L115	False	CDR3	L	10257	10257_seq2	IGLV1-50*01	IGLV1	lupartumab amadotin	Human	ESVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYVVHWYQQLPGTAPKLLIYDNNKRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDRLNGPVFGGGTKLTVL
site293	NG	N	54	H54	H62	True	CDR2	H	10078	10078_seq1	IGHV1-3*01	IGHV1	lutetium (177lu) lilotomab satetraxetan	Mouse	EIQLQQSGPELVKPGASVKVSCKASGYSFTDYNMYWVKQSHGKSLEWIGYIDPYNGDTTYNQKFKGKATLTVDKSSSTAFIHLNSLTSEDSAVYYCARSPYGHYAMDYWGQGTSVTVSS
site294	NG	N+1	55	H55	H63	True	CDR2	H	10078	10078_seq1	IGHV1-3*01	IGHV1	lutetium (177lu) lilotomab satetraxetan	Mouse	EIQLQQSGPELVKPGASVKVSCKASGYSFTDYNMYWVKQSHGKSLEWIGYIDPYNGDTTYNQKFKGKATLTVDKSSSTAFIHLNSLTSEDSAVYYCARSPYGHYAMDYWGQGTSVTVSS
site295	NG	N	32	L28	L34	True	CDR1	K	10999	10999_seq1	IGKV2-28*01	IGKV2	magrolimab	Humanized/Chimeric	DIVMTQSPLSLPVTPGEPASISCRSSQSIVYSNGNTYLGWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGQGTKLEIK
site296	NG	N+1	33	L29	L35	True	CDR1	K	10999	10999_seq1	IGKV2-28*01	IGKV2	magrolimab	Humanized/Chimeric	DIVMTQSPLSLPVTPGEPASISCRSSQSIVYSNGNTYLGWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGQGTKLEIK
site297	NG	N	95	L94	L113	False	CDR3	L	11133	11133_seq2	IGLV8-61*01	IGLV8	manelimab	Human	QTVVTQEPSLSVSPGGTVTLTCGLSSGTVTAINYPGWYQQTPGQAPRTLIYNTNTRHSGVPDRFSGSISGNKAALTITGAQAEDEADYYCALYMGNGGHMFGGGTKLTVL
site298	NG	N+1	96	L95	L114	False	CDR3	L	11133	11133_seq2	IGLV8-61*01	IGLV8	manelimab	Human	QTVVTQEPSLSVSPGGTVTLTCGLSSGTVTAINYPGWYQQTPGQAPRTLIYNTNTRHSGVPDRFSGSISGNKAALTITGAQAEDEADYYCALYMGNGGHMFGGGTKLTVL
site299	NG	N	54	H54	H62	False	CDR2	H	9799	9799_seq1	IGHV1-2*06	IGHV1	margetuximab	Chimeric	QVQLQQSGPELVKPGASLKLSCTASGFNIKDTYIHWVKQRPEQGLEWIGRIYPTNGYTRYDPKFQDKATITADTSSNTAYLQVSRLTSEDTAVYYCSRWGGDGFYAMDYWGQGASVTVSS
site300	NG	N+1	55	H55	H63	True	CDR2	H	9799	9799_seq1	IGHV1-2*06	IGHV1	margetuximab	Chimeric	QVQLQQSGPELVKPGASLKLSCTASGFNIKDTYIHWVKQRPEQGLEWIGRIYPTNGYTRYDPKFQDKATITADTSSNTAYLQVSRLTSEDTAVYYCSRWGGDGFYAMDYWGQGASVTVSS
site301	DG	N	101	H98	H110	False	CDR3	H	9799	9799_seq1	IGHV1-2*06	IGHV1	margetuximab	Chimeric	QVQLQQSGPELVKPGASLKLSCTASGFNIKDTYIHWVKQRPEQGLEWIGRIYPTNGYTRYDPKFQDKATITADTSSNTAYLQVSRLTSEDTAVYYCSRWGGDGFYAMDYWGQGASVTVSS
site302	DG	N+1	102	H99	H111	False	CDR3	H	9799	9799_seq1	IGHV1-2*06	IGHV1	margetuximab	Chimeric	QVQLQQSGPELVKPGASLKLSCTASGFNIKDTYIHWVKQRPEQGLEWIGRIYPTNGYTRYDPKFQDKATITADTSSNTAYLQVSRLTSEDTAVYYCSRWGGDGFYAMDYWGQGASVTVSS
site303	NG	N	53	H53	H59	False	CDR2	H	11159	11159_seq1	IGHV3-23*01	IGHV3	mezagitamab	Humanized	EVQLLESGGGLVQPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSDISWNGGKTHYVDSVKGQFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSLFHDSSGFYFGHWGQGTLVTVSS
site304	NG	N+1	54	H54	H62	True	CDR2	H	11159	11159_seq1	IGHV3-23*01	IGHV3	mezagitamab	Humanized	EVQLLESGGGLVQPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSDISWNGGKTHYVDSVKGQFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSLFHDSSGFYFGHWGQGTLVTVSS
site305	NG	N	32	L28	L34	False	CDR1	K	8922	8922_seq1	IGKV2-30*02	IGKV2	milatuzumab	Humanized	DIQLTQSPLSLPVTLGQPASISCRSSQSLVHRNGNTYLHWFQQRPGQSPRLLIYTVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSSHVPPTFGAGTRLEIK
site306	NG	N+1	33	L29	L35	True	CDR1	K	8922	8922_seq1	IGKV2-30*02	IGKV2	milatuzumab	Humanized	DIQLTQSPLSLPVTLGQPASISCRSSQSLVHRNGNTYLHWFQQRPGQSPRLLIYTVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSSHVPPTFGAGTRLEIK
site307	DG	N	55	H55	H63	False	CDR2	H	10657	10657_seq1	IGHV1-2*02	IGHV1	mirikizumab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYKFTRYVMHWVRQAPGQGLEWMGYINPYNDGTNYNEKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNWDTGLWGQGTTVTVSS
site308	DG	N+1	56	H56	H64	True	CDR2	H	10657	10657_seq1	IGHV1-2*02	IGHV1	mirikizumab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYKFTRYVMHWVRQAPGQGLEWMGYINPYNDGTNYNEKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNWDTGLWGQGTTVTVSS
site309	DG	N	101	H98	H110	False	CDR3	H	11199	11199_seq1	IGHV1-2*02	IGHV1	miromavimab	Mouse	QVQLQQPGSVLVRPGASVKLSCKTSGYAFTSSWMHWAKQRPGQGLEWIGQTHPNSGYTNYNEKFKGKATLTVDTSSSTAYVDLSSLTSEDSAVYYCARESGDGPHWYFDVWGAGTAVTVSS
site310	DG	N+1	102	H99	H111	False	CDR3	H	11199	11199_seq1	IGHV1-2*02	IGHV1	miromavimab	Mouse	QVQLQQPGSVLVRPGASVKLSCKTSGYAFTSSWMHWAKQRPGQGLEWIGQTHPNSGYTNYNEKFKGKATLTVDTSSSTAYVDLSSLTSEDSAVYYCARESGDGPHWYFDVWGAGTAVTVSS
site311	DG	N	54	H54	H62	False	CDR2	H	10187	10187_seq1	IGHV1-2*06	IGHV1	mirvetuximab	Chimeric	QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFYNQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRAMDYWGQGTTVTVSS
site312	DG	N+1	55	H55	H63	True	CDR2	H	10187	10187_seq1	IGHV1-2*06	IGHV1	mirvetuximab	Chimeric	QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFYNQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRAMDYWGQGTTVTVSS
site313	DG	N	99	H96	H108	False	CDR3	H	10187	10187_seq1	IGHV1-2*06	IGHV1	mirvetuximab	Chimeric	QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFYNQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRAMDYWGQGTTVTVSS
site314	DG	N+1	100	H97	H109	False	CDR3	H	10187	10187_seq1	IGHV1-2*06	IGHV1	mirvetuximab	Chimeric	QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFYNQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRAMDYWGQGTTVTVSS
site315	DG	N	54	H54	H62	False	CDR2	H	10176	10176_seq1	IGHV1-2*06	IGHV1	mirvetuximab soravtansine	Chimeric	QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFYNQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRAMDYWGQGTTVTVSS
site316	DG	N+1	55	H55	H63	True	CDR2	H	10176	10176_seq1	IGHV1-2*06	IGHV1	mirvetuximab soravtansine	Chimeric	QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFYNQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRAMDYWGQGTTVTVSS
site317	DG	N	99	H96	H108	False	CDR3	H	10176	10176_seq1	IGHV1-2*06	IGHV1	mirvetuximab soravtansine	Chimeric	QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFYNQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRAMDYWGQGTTVTVSS
site318	DG	N+1	100	H97	H109	False	CDR3	H	10176	10176_seq1	IGHV1-2*06	IGHV1	mirvetuximab soravtansine	Chimeric	QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFYNQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRAMDYWGQGTTVTVSS
site319	NG	N	32	L28	L34	True	CDR1	K	9613	9613_seq2	IGKV2-28*01	IGKV2	modotuximab	Chimeric	DIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPYTFGGGTKLEIK
site320	NG	N+1	33	L29	L35	True	CDR1	K	9613	9613_seq2	IGKV2-28*01	IGKV2	modotuximab	Chimeric	DIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPYTFGGGTKLEIK
site321	NG	N	32	L28	L34	True	CDR1	K	9374	9374_seq1	IGKV2-28*01	IGKV2	mogamulizumab	Humanized	DVLMTQSPLSLPVTPGEPASISCRSSRNIVHINGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLLPWTFGQGTKVEIK
site322	NG	N+1	33	L29	L35	True	CDR1	K	9374	9374_seq1	IGKV2-28*01	IGKV2	mogamulizumab	Humanized	DVLMTQSPLSLPVTPGEPASISCRSSRNIVHINGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLLPWTFGQGTKVEIK
site323	DG	N	100	H97	H109	False	CDR3	H	9374	9374_seq2	IGHV3-21*01	IGHV3	mogamulizumab	Humanized	EVQLVESGGDLVQPGRSLRLSCAASGFIFSNYGMSWVRQAPGKGLEWVATISSASTYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRVEDTALYYCGRHSDGNFAFGYWGQGTLVTVSS
site324	DG	N+1	101	H98	H110	False	CDR3	H	9374	9374_seq2	IGHV3-21*01	IGHV3	mogamulizumab	Humanized	EVQLVESGGDLVQPGRSLRLSCAASGFIFSNYGMSWVRQAPGKGLEWVATISSASTYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRVEDTALYYCGRHSDGNFAFGYWGQGTLVTVSS
site325	DG	N	54	H54	H62	False	CDR2	H	10621	10621_seq2	IGHV1-3*01	IGHV1	mosunetuzumab	Humanized	EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQGLEWIGWIYPGDGNTKYNEKFKGRATLTADTSTSTAYLELSSLRSEDTAVYYCARDSYSNYYFDYWGQGTLVTVSS
site326	DG	N+1	55	H55	H63	True	CDR2	H	10621	10621_seq2	IGHV1-3*01	IGHV1	mosunetuzumab	Humanized	EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQGLEWIGWIYPGDGNTKYNEKFKGRATLTADTSTSTAYLELSSLRSEDTAVYYCARDSYSNYYFDYWGQGTLVTVSS
site327	NG	N	54	H54	H62	False	CDR2	H	10621	10621_seq4	IGHV3-23*04	IGHV3	mosunetuzumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS
site328	NG	N+1	55	H55	H63	True	CDR2	H	10621	10621_seq4	IGHV3-23*04	IGHV3	mosunetuzumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS
site329	DG	N	54	H54	H62	False	CDR2	H	11039	11039_seq2	IGHV1-69*02	IGHV1	nadunolimab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYAFTSSWMNWVRQAPGQGLEWMGRIYPGDGNTHYAQKFQGRVTLTADKSTSTAYMELSSLRSEDTAVYYCGEGYLDPMDYWGQGTLVTVSS
site330	DG	N+1	55	H55	H63	True	CDR2	H	11039	11039_seq2	IGHV1-69*02	IGHV1	nadunolimab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYAFTSSWMNWVRQAPGQGLEWMGRIYPGDGNTHYAQKFQGRVTLTADKSTSTAYMELSSLRSEDTAVYYCGEGYLDPMDYWGQGTLVTVSS
site331	NG	N	54	H54	H62	False	CDR2	H	8598	8598_seq2	IGHV1-2*06	IGHV1	naptumomab estafenatox	Mouse	EVQLQQSGPDLVKPGASVKISCKASGYSFTGYYMHWVKQSPGKGLEWIGRINPNNGVTLYNQKFKDKATLTVDKSSTTAYMELRSLTSEDSAVYYCARSTMITNYVMDYWGQGTSVTVSS
site332	NG	N+1	55	H55	H63	True	CDR2	H	8598	8598_seq2	IGHV1-2*06	IGHV1	naptumomab estafenatox	Mouse	EVQLQQSGPDLVKPGASVKISCKASGYSFTGYYMHWVKQSPGKGLEWIGRINPNNGVTLYNQKFKDKATLTVDKSSTTAYMELRSLTSEDSAVYYCARSTMITNYVMDYWGQGTSVTVSS
site333	DG	N	53	H54	H59	False	CDR2	H	10239	10239_seq2	IGHV4-4*08	IGHV4	naratuximab	Chimeric	QVQVQESGPGLVAPSQTLSITCTVSGFSLTTSGVSWVRQPPGKGLEWLGVIWGDGSTNYHPSLKSRLSIKKDHSKSQVFLKLNSLTAADTATYYCAKGGYSLAHWGQGTLVTVSS
site334	DG	N+1	54	H55	H63	True	CDR2	H	10239	10239_seq2	IGHV4-4*08	IGHV4	naratuximab	Chimeric	QVQVQESGPGLVAPSQTLSITCTVSGFSLTTSGVSWVRQPPGKGLEWLGVIWGDGSTNYHPSLKSRLSIKKDHSKSQVFLKLNSLTAADTATYYCAKGGYSLAHWGQGTLVTVSS
site335	DG	N	53	H54	H59	False	CDR2	H	10238	10238_seq2	IGHV4-4*08	IGHV4	naratuximab emtansine	Chimeric	QVQVQESGPGLVAPSQTLSITCTVSGFSLTTSGVSWVRQPPGKGLEWLGVIWGDGSTNYHPSLKSRLSIKKDHSKSQVFLKLNSLTAADTATYYCAKGGYSLAHWGQGTLVTVSS
site336	DG	N+1	54	H55	H63	True	CDR2	H	10238	10238_seq2	IGHV4-4*08	IGHV4	naratuximab emtansine	Chimeric	QVQVQESGPGLVAPSQTLSITCTVSGFSLTTSGVSWVRQPPGKGLEWLGVIWGDGSTNYHPSLKSRLSIKKDHSKSQVFLKLNSLTAADTATYYCAKGGYSLAHWGQGTLVTVSS
site337	DG	N	53	H53	H59	True	CDR2	H	9447	9447_seq2	IGHV3-7*01	IGHV3	narnatumab	Human	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYLMTWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLNLQMNSLRAEDTAVYYCTRDGYSSGRHYGMDVWGQGTTVIVSS
site338	DG	N+1	54	H54	H62	True	CDR2	H	9447	9447_seq2	IGHV3-7*01	IGHV3	narnatumab	Human	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYLMTWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLNLQMNSLRAEDTAVYYCTRDGYSSGRHYGMDVWGQGTTVIVSS
site339	DG	N	98	H95	H107	False	CDR3	H	9447	9447_seq2	IGHV3-7*01	IGHV3	narnatumab	Human	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYLMTWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLNLQMNSLRAEDTAVYYCTRDGYSSGRHYGMDVWGQGTTVIVSS
site340	DG	N+1	99	H96	H108	False	CDR3	H	9447	9447_seq2	IGHV3-7*01	IGHV3	narnatumab	Human	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYLMTWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLNLQMNSLRAEDTAVYYCTRDGYSSGRHYGMDVWGQGTTVIVSS
site341	NG	N	54	H54	H62	False	CDR2	H	10220	10220_seq2	IGHV1-46*01	IGHV1	navicixizumab	Humanized/Chimeric	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGDINPSNGRTSYKEKFKRRVTLSVDKSSSTAYMELSSLRSEDTAVYFCTIHYDDKYYPLMDYWGQGTLVTVSS
site342	NG	N+1	55	H55	H63	True	CDR2	H	10220	10220_seq2	IGHV1-46*01	IGHV1	navicixizumab	Humanized/Chimeric	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGDINPSNGRTSYKEKFKRRVTLSVDKSSSTAYMELSSLRSEDTAVYFCTIHYDDKYYPLMDYWGQGTLVTVSS
site343	NG	N	54	H54	H62	False	CDR2	H	10064	10064_seq2	IGHV1-2*02	IGHV1	nemolizumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYIMNWVRQAPGQGLEWMGLINPYNGGTDYNPQFQDRVTITADKSTSTAYMELSSLRSEDTAVYYCARDGYDDGPYTLETWGQGTLVTVSS
site344	NG	N+1	55	H55	H63	True	CDR2	H	10064	10064_seq2	IGHV1-2*02	IGHV1	nemolizumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYIMNWVRQAPGQGLEWMGLINPYNGGTDYNPQFQDRVTITADKSTSTAYMELSSLRSEDTAVYYCARDGYDDGPYTLETWGQGTLVTVSS
site345	DG	N	98	H95	H107	False	CDR3	H	10064	10064_seq2	IGHV1-2*02	IGHV1	nemolizumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYIMNWVRQAPGQGLEWMGLINPYNGGTDYNPQFQDRVTITADKSTSTAYMELSSLRSEDTAVYYCARDGYDDGPYTLETWGQGTLVTVSS
site346	DG	N+1	99	H96	H108	False	CDR3	H	10064	10064_seq2	IGHV1-2*02	IGHV1	nemolizumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYIMNWVRQAPGQGLEWMGLINPYNGGTDYNPQFQDRVTITADKSTSTAYMELSSLRSEDTAVYYCARDGYDDGPYTLETWGQGTLVTVSS
site347	DG	N	102	H99	H111	False	CDR3	H	10064	10064_seq2	IGHV1-2*02	IGHV1	nemolizumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYIMNWVRQAPGQGLEWMGLINPYNGGTDYNPQFQDRVTITADKSTSTAYMELSSLRSEDTAVYYCARDGYDDGPYTLETWGQGTLVTVSS
site348	DG	N+1	103	H100	H112A	False	CDR3	H	10064	10064_seq2	IGHV1-2*02	IGHV1	nemolizumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYIMNWVRQAPGQGLEWMGLINPYNGGTDYNPQFQDRVTITADKSTSTAYMELSSLRSEDTAVYYCARDGYDDGPYTLETWGQGTLVTVSS
site349	DG	N	54	H54	H62	False	CDR2	H	11023	11023_seq1	IGHV1-69*02	IGHV1	nimacimab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYEFSYYWMNWVRQAPGQGLEWMGQIYPGDGETKYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSHGNYLPYWGQGTLVTVSS
site350	DG	N+1	55	H55	H63	True	CDR2	H	11023	11023_seq1	IGHV1-69*02	IGHV1	nimacimab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYEFSYYWMNWVRQAPGQGLEWMGQIYPGDGETKYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSHGNYLPYWGQGTLVTVSS
site351	DG	N	105	H100B	H112A	False	CDR3	H	8545	8545_seq1	IGHV1-69*01	IGHV1	nimotuzumab	Humanized	QVQLQQSGAEVKKPGSSVKVSCKASGYTFTNYYIYWVRQAPGQGLEWIGGINPTSGGSNFNEKFKTRVTITVDESTNTAYMELSSLRSEDTAFYFCARQGLWFDSDGRGFDFWGQGSTVTVSS
site352	DG	N+1	106	H100C	H112	False	CDR3	H	8545	8545_seq1	IGHV1-69*01	IGHV1	nimotuzumab	Humanized	QVQLQQSGAEVKKPGSSVKVSCKASGYTFTNYYIYWVRQAPGQGLEWIGGINPTSGGSNFNEKFKTRVTITVDESTNTAYMELSSLRSEDTAFYFCARQGLWFDSDGRGFDFWGQGSTVTVSS
site353	NG	N	32	L28	L34	False	CDR1	K	8545	8545_seq2	IGKV1-33*01	IGKV1	nimotuzumab	Humanized	DIQMTQSPSSLSASVGDRVTITCRSSQNIVHSNGNTYLDWYQQTPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFQYSHVPWTFGQGTKLQIT
site354	NG	N+1	33	L29	L35	False	CDR1	K	8545	8545_seq2	IGKV1-33*01	IGKV1	nimotuzumab	Humanized	DIQMTQSPSSLSASVGDRVTITCRSSQNIVHSNGNTYLDWYQQTPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFQYSHVPWTFGQGTKLQIT
site355	DG	N	53	H53	H59	True	CDR2	H	9623	9623_seq1	IGHV3-33*01	IGHV3	nivolumab	Human	QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS
site356	DG	N+1	54	H54	H62	True	CDR2	H	9623	9623_seq1	IGHV3-33*01	IGHV3	nivolumab	Human	QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS
site357	DG	N	53	H53	H59	True	CDR2	H	11141	11141_seq1	IGHV3-30*01	IGHV3	nurulimab	Human	EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS
site358	DG	N+1	54	H54	H62	True	CDR2	H	11141	11141_seq1	IGHV3-30*01	IGHV3	nurulimab	Human	EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS
site359	NG	N	32	L28	L34	False	CDR1	K	10898	10898_seq1	IGKV3-11*01	IGKV3	obexelimab	Chimeric	DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK
site360	NG	N+1	33	L29	L35	False	CDR1	K	10898	10898_seq1	IGKV3-11*01	IGKV3	obexelimab	Chimeric	DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK
site361	DG	N	55	H55	H63	False	CDR2	H	10898	10898_seq2	IGHV1-3*01	IGHV1	obexelimab	Chimeric	EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS
site362	DG	N+1	56	H56	H64	False	CDR2	H	10898	10898_seq2	IGHV1-3*01	IGHV1	obexelimab	Chimeric	EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS
site363	NG	N	60	H60	H68	False	CDR2	H	9825	9825_seq2	IGHV1-69*02	IGHV1	obiltoxaximab	Chimeric	QVQLQQSGPELKKPGASVKVSCKDSGYAFSSSWMNWVRQAPGQGLEWIGRIYPGDGDTNYNGKFQGRVTITADKSSSTAYMELSSLRSEDTAVYFCARSGLLRYAMDYWGQGTLVTVSS
site364	NG	N+1	61	H61	H69	False	CDR2	H	9825	9825_seq2	IGHV1-69*02	IGHV1	obiltoxaximab	Chimeric	QVQLQQSGPELKKPGASVKVSCKDSGYAFSSSWMNWVRQAPGQGLEWIGRIYPGDGDTNYNGKFQGRVTITADKSSSTAYMELSSLRSEDTAVYFCARSGLLRYAMDYWGQGTLVTVSS
site365	DG	N	54	H54	H62	False	CDR2	H	9825	9825_seq2	IGHV1-69*02	IGHV1	obiltoxaximab	Chimeric	QVQLQQSGPELKKPGASVKVSCKDSGYAFSSSWMNWVRQAPGQGLEWIGRIYPGDGDTNYNGKFQGRVTITADKSSSTAYMELSSLRSEDTAVYFCARSGLLRYAMDYWGQGTLVTVSS
site366	DG	N+1	55	H55	H63	True	CDR2	H	9825	9825_seq2	IGHV1-69*02	IGHV1	obiltoxaximab	Chimeric	QVQLQQSGPELKKPGASVKVSCKDSGYAFSSSWMNWVRQAPGQGLEWIGRIYPGDGDTNYNGKFQGRVTITADKSSSTAYMELSSLRSEDTAVYFCARSGLLRYAMDYWGQGTLVTVSS
site367	NG	N	60	H60	H68	False	CDR2	H	9043	9043_seq1	IGHV1-69*02	IGHV1	obinutuzumab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS
site368	NG	N+1	61	H61	H69	False	CDR2	H	9043	9043_seq1	IGHV1-69*02	IGHV1	obinutuzumab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS
site369	DG	N	54	H54	H62	False	CDR2	H	9043	9043_seq1	IGHV1-69*02	IGHV1	obinutuzumab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS
site370	DG	N+1	55	H55	H63	True	CDR2	H	9043	9043_seq1	IGHV1-69*02	IGHV1	obinutuzumab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS
site371	DG	N	101	H98	H110	False	CDR3	H	9043	9043_seq1	IGHV1-69*02	IGHV1	obinutuzumab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS
site372	DG	N+1	102	H99	H112	False	CDR3	H	9043	9043_seq1	IGHV1-69*02	IGHV1	obinutuzumab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS
site373	NG	N	32	L28	L34	True	CDR1	K	9043	9043_seq2	IGKV2-28*01	IGKV2	obinutuzumab	Humanized	DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK
site374	NG	N+1	33	L29	L35	True	CDR1	K	9043	9043_seq2	IGKV2-28*01	IGKV2	obinutuzumab	Humanized	DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK
site375	DG	N	101	H98	H110	False	CDR3	H	10037	10037_seq1	IGHV1-46*01	IGHV1	olendalizumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPGQGLEWMGAIHLNTGYTNYNQKFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGFYDGYSPMDYWGQGTTVTVSS
site376	DG	N+1	102	H99	H111	False	CDR3	H	10037	10037_seq1	IGHV1-46*01	IGHV1	olendalizumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPGQGLEWMGAIHLNTGYTNYNQKFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGFYDGYSPMDYWGQGTTVTVSS
site377	NG	N	54	H54	H62	True	CDR2	H	10829	10829_seq1	IGHV1-3*01	IGHV1	olinvacimab	Humanized	QMQLVQSGAEVKKPGASVKLSCKASGYTFSSYWMHWVRQAPGQRLEWMGEINPGNGHTNYNEKFKSRVTITVDKSASTAYMELSSLRSEDTAVYYCAKIWGPSLTSPFDYWGQGTLVTVSS
site378	NG	N+1	55	H55	H63	True	CDR2	H	10829	10829_seq1	IGHV1-3*01	IGHV1	olinvacimab	Humanized	QMQLVQSGAEVKKPGASVKLSCKASGYTFSSYWMHWVRQAPGQRLEWMGEINPGNGHTNYNEKFKSRVTITVDKSASTAYMELSSLRSEDTAVYYCAKIWGPSLTSPFDYWGQGTLVTVSS
site379	DG	N	31	L28	L34	False	CDR1	K	8039	8039_seq1	IGKV1-39*01	IGKV1	omalizumab	Humanized	DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIK
site380	DG	N+1	32	L29	L35	False	CDR1	K	8039	8039_seq1	IGKV1-39*01	IGKV1	omalizumab	Humanized	DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIK
site381	DG	N	54	H54	H59	False	CDR2	H	8039	8039_seq2	IGHV3-66*01	IGHV3	omalizumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYNPSVKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS
site382	DG	N+1	55	H55	H63	True	CDR2	H	8039	8039_seq2	IGHV3-66*01	IGHV3	omalizumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYNPSVKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS
site383	DG	N	54	H54	H62	False	CDR2	H	10803	10803_seq1	IGHV1-2*02	IGHV1	omburtamab	Mouse	QVQLQQSGAELVKPGASVKLSCKASGYTFTNYDINWVRQRPEQGLEWIGWIFPGDGSTQYNEKFKGKATLTTDTSSSTAYMQLSRLTSEDSAVYFCARQTTATWFAYWGQGTLVTVSA
site384	DG	N+1	55	H55	H63	True	CDR2	H	10803	10803_seq1	IGHV1-2*02	IGHV1	omburtamab	Mouse	QVQLQQSGAELVKPGASVKLSCKASGYTFTNYDINWVRQRPEQGLEWIGWIFPGDGSTQYNEKFKGKATLTTDTSSSTAYMQLSRLTSEDSAVYFCARQTTATWFAYWGQGTLVTVSA
site385	NG	N	89	L90	L106	False	CDR3	K	10803	10803_seq2	IGKV6-21*02	IGKV6	omburtamab	Mouse	DIVMTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGSDFTLSINSVEPEDVGVYYCQNGHSFPLTFGAGTKLELK
site386	NG	N+1	90	L91	L107	False	CDR3	K	10803	10803_seq2	IGKV6-21*02	IGKV6	omburtamab	Mouse	DIVMTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGSDFTLSINSVEPEDVGVYYCQNGHSFPLTFGAGTKLELK
site387	DG	N	32	L28	L34	True	CDR1	K	10903	10903_seq1	IGKV2D-29*01	IGKV2D	ontamalimab	Human	DIVMTQTPLSLSVTPGQPASISCKSSQSLLHTDGTTYLYWYLQKPGQPPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCMQNIQLPWTFGQGTKVEIK
site388	DG	N+1	33	L29	L35	True	CDR1	K	10903	10903_seq1	IGKV2D-29*01	IGKV2D	ontamalimab	Human	DIVMTQTPLSLSVTPGQPASISCKSSQSLLHTDGTTYLYWYLQKPGQPPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCMQNIQLPWTFGQGTKVEIK
site389	DG	N	103	H100	H111A	False	CDR3	H	9519	9519_seq1	IGHV4-30-4*01	IGHV4	ontuxizumab	Humanized/Chimeric	QVQLQESGPGLVRPSQTLSLTCTASGYTFTDYVIHWVKQPPGRGLEWIGYINPYDDDTTYNQKFKGRVTMLVDTSSNTAYLRLSSVTAEDTAVYYCARRGNSYDGYFDYSMDYWGSGTPVTVSS
site390	DG	N+1	104	H100A	H111B	False	CDR3	H	9519	9519_seq1	IGHV4-30-4*01	IGHV4	ontuxizumab	Humanized/Chimeric	QVQLQESGPGLVRPSQTLSLTCTASGYTFTDYVIHWVKQPPGRGLEWIGYINPYDDDTTYNQKFKGRVTMLVDTSSNTAYLRLSSVTAEDTAVYYCARRGNSYDGYFDYSMDYWGSGTPVTVSS
site391	NG	N	96	L95A	L114	False	CDR3	L	9635	9635_seq2	IGLV1-47*01	IGLV1	orticumab	Human	QSVLTQPPSASGTPGQRVTISCSGSNTNIGKNYVSWYQQLPGTAPKLLIYANSNRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCASWDASLNGWVFGGGTKLTVL
site392	NG	N+1	97	L95B	L115	False	CDR3	L	9635	9635_seq2	IGLV1-47*01	IGLV1	orticumab	Human	QSVLTQPPSASGTPGQRVTISCSGSNTNIGKNYVSWYQQLPGTAPKLLIYANSNRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCASWDASLNGWVFGGGTKLTVL
site393	NG	N	54	H54	H62	False	CDR2	H	9703	9703_seq1	IGHV1-46*01	IGHV1	ozanezumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSKATMTRDTSTSTAYMELSSLRSEDTAVYYCELMQGYWGQGTLVTVSS
site394	NG	N+1	55	H55	H63	True	CDR2	H	9703	9703_seq1	IGHV1-46*01	IGHV1	ozanezumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSKATMTRDTSTSTAYMELSSLRSEDTAVYYCELMQGYWGQGTLVTVSS
site395	DG	N	32	L28	L34	True	CDR1	K	9703	9703_seq2	IGKV2-30*01	IGKV2	ozanezumab	Humanized	DIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFLQRPGQSPQLLIYLMSTRASGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK
site396	DG	N+1	33	L29	L35	True	CDR1	K	9703	9703_seq2	IGKV2-30*01	IGKV2	ozanezumab	Humanized	DIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFLQRPGQSPQLLIYLMSTRASGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK
site397	NG	N	32	L28	L34	False	CDR1	K	10995	10995_seq2	IGKV2D-29*02	IGKV2D	pabinafusp alfa	Humanized	DIVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK
site398	NG	N+1	33	L29	L35	True	CDR1	K	10995	10995_seq2	IGKV2D-29*02	IGKV2D	pabinafusp alfa	Humanized	DIVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK
site399	NG	N	91	L92	L108	False	CDR3	K	10938	10938_seq1	IGKV1-39*01	IGKV1	pacmilimab	Human	DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQDNGYPSTFGGGTKVEIK
site400	NG	N+1	92	L93	L109	False	CDR3	K	10938	10938_seq1	IGKV1-39*01	IGKV1	pacmilimab	Human	DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQDNGYPSTFGGGTKVEIK
site401	NG	N	53	H53	H59	False	CDR2	H	10938	10938_seq2	IGHV3-23*01	IGHV3	pacmilimab	Human	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSSIWRNGIVTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKWSAAFDYWGQGTLVTVSS
site402	NG	N+1	54	H54	H62	True	CDR2	H	10938	10938_seq2	IGHV3-23*01	IGHV3	pacmilimab	Human	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSSIWRNGIVTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKWSAAFDYWGQGTLVTVSS
site403	DG	N	53	H54	H59	True	CDR2	H	8888	8888_seq1	IGHV3-74*01	IGHV3	panobacumab	Human	EEQVVESGGGFVQPGGSLRLSCAASGFTFSPYWMHWVRQAPGKGLVWVSRINSDGSTYYADSVKGRFTISRDNARNTLYLQMNSLRAEDTAVYYCARDRYYGPEMWGQGTMVTVSS
site404	DG	N+1	54	H55	H63	False	CDR2	H	8888	8888_seq1	IGHV3-74*01	IGHV3	panobacumab	Human	EEQVVESGGGFVQPGGSLRLSCAASGFTFSPYWMHWVRQAPGKGLVWVSRINSDGSTYYADSVKGRFTISRDNARNTLYLQMNSLRAEDTAVYYCARDRYYGPEMWGQGTMVTVSS
site405	DG	N	32	L28	L34	True	CDR1	K	8888	8888_seq2	IGKV2-30*01	IGKV2	panobacumab	Human	DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGGGTKVEIK
site406	DG	N+1	33	L29	L35	True	CDR1	K	8888	8888_seq2	IGKV2-30*01	IGKV2	panobacumab	Human	DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGGGTKVEIK
site407	NG	N	54	H54	H62	False	CDR2	H	9798	9798_seq2	IGHV1-2*02	IGHV1	pembrolizumab	Humanized	QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS
site408	NG	N+1	55	H55	H63	True	CDR2	H	9798	9798_seq2	IGHV1-2*02	IGHV1	pembrolizumab	Humanized	QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS
site409	DG	N	31	L28	L34	False	CDR1	K	11011	11011_seq2	IGKV4-1*01	IGKV4	pepinemab	Humanized/Chimeric	DIVMTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPYTFGQGTKLEIK
site410	DG	N+1	32	L29	L35	False	CDR1	K	11011	11011_seq2	IGKV4-1*01	IGKV4	pepinemab	Humanized/Chimeric	DIVMTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPYTFGQGTKLEIK
site411	DG	N	98	H95	H107	False	CDR3	H	9648	9648_seq1	IGHV3-7*01	IGHV3	perakizumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYTMLWVRQAPGKGLEWVAIIKSGGSYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGDYGSSYGAMDYWGQGTLVTVSS
site412	DG	N+1	99	H96	H108	False	CDR3	H	9648	9648_seq1	IGHV3-7*01	IGHV3	perakizumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYTMLWVRQAPGKGLEWVAIIKSGGSYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGDYGSSYGAMDYWGQGTLVTVSS
site413	DG	N	54	H54	H62	False	CDR2	H	9713	9713_seq2	IGHV3-66*01	IGHV3	pinatuzumab vedotin	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGYEFSRSWMNWVRQAPGKGLEWVGRIYPGDGDTNYSGKFKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDGSSWDWYFDVWGQGTLVTVSS
site414	DG	N+1	55	H55	H63	True	CDR2	H	9713	9713_seq2	IGHV3-66*01	IGHV3	pinatuzumab vedotin	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGYEFSRSWMNWVRQAPGKGLEWVGRIYPGDGDTNYSGKFKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDGSSWDWYFDVWGQGTLVTVSS
site415	DG	N	98	H95	H107	False	CDR3	H	9713	9713_seq2	IGHV3-66*01	IGHV3	pinatuzumab vedotin	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGYEFSRSWMNWVRQAPGKGLEWVGRIYPGDGDTNYSGKFKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDGSSWDWYFDVWGQGTLVTVSS
site416	DG	N+1	99	H96	H108	False	CDR3	H	9713	9713_seq2	IGHV3-66*01	IGHV3	pinatuzumab vedotin	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGYEFSRSWMNWVRQAPGKGLEWVGRIYPGDGDTNYSGKFKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDGSSWDWYFDVWGQGTLVTVSS
site417	NG	N	54	H54	H62	True	CDR2	H	11020	11020_seq1	IGHV1-3*01	IGHV1	plamotamab	Humanized/Chimeric	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGAIYPGNGDTSYNQKFQGRVTITADKSISTAYMELSSLRSEDTAVYYCARSTYYGGDWYFNVWGAGTLVTVSS
site418	NG	N+1	55	H55	H63	True	CDR2	H	11020	11020_seq1	IGHV1-3*01	IGHV1	plamotamab	Humanized/Chimeric	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGAIYPGNGDTSYNQKFQGRVTITADKSISTAYMELSSLRSEDTAVYYCARSTYYGGDWYFNVWGAGTLVTVSS
site419	DG	N	32	L28	L34	True	CDR1	K	10124	10124_seq1	IGKV2-30*01	IGKV2	plozalizumab	Humanized	DVVMTQSPLSLPVTLGQPASISCKSSQSLLDSDGKTFLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPYTFGQGTRLEIK
site420	DG	N+1	33	L29	L35	True	CDR1	K	10124	10124_seq1	IGKV2-30*01	IGKV2	plozalizumab	Humanized	DVVMTQSPLSLPVTLGQPASISCKSSQSLLDSDGKTFLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPYTFGQGTRLEIK
site421	NG	N	103	H98	H115	False	CDR3	H	10124	10124_seq2	IGHV3-15*07	IGHV3	plozalizumab	Humanized	EVQLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNWVRQAPGKGLEWVGRIRTKNNNYATYYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNGVWGQGTLVTVSS
site422	NG	N+1	104	H101	H116	False	CDR3	H	10124	10124_seq2	IGHV3-15*07	IGHV3	plozalizumab	Humanized	EVQLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNWVRQAPGKGLEWVGRIRTKNNNYATYYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNGVWGQGTLVTVSS
site423	NG	N	101	H96	H108	False	CDR3	H	10536	10536_seq2	IGHV3-73*01	IGHV3	porgaviximab	Chimeric	EVQLQESGGGLMQPGGSMKLSCVASGFTFSNYWMNWVRQSPEKGLEWVAEIRLKSNNYATHYAESVKGRFTISRDDSKRSVYLQMNTLRAEDTGIYYCTRGNGNYRAMDYWGQGTSVTVSS
site424	NG	N+1	102	H97	H109	False	CDR3	H	10536	10536_seq2	IGHV3-73*01	IGHV3	porgaviximab	Chimeric	EVQLQESGGGLMQPGGSMKLSCVASGFTFSNYWMNWVRQSPEKGLEWVAEIRLKSNNYATHYAESVKGRFTISRDDSKRSVYLQMNTLRAEDTGIYYCTRGNGNYRAMDYWGQGTSVTVSS
site425	NG	N	32	L28	L34	True	CDR1	K	10940	10940_seq1	IGKV2-28*01	IGKV2	praluzatamab	Humanized	DIVMTQSPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGQGTKLEIK
site426	NG	N+1	33	L29	L35	True	CDR1	K	10940	10940_seq1	IGKV2-28*01	IGKV2	praluzatamab	Humanized	DIVMTQSPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGQGTKLEIK
site427	NG	N	32	L28	L34	True	CDR1	K	10939	10939_seq1	IGKV2-28*01	IGKV2	praluzatamab ravtansine	Humanized	DIVMTQSPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGQGTKLEIK
site428	NG	N+1	33	L29	L35	True	CDR1	K	10939	10939_seq1	IGKV2-28*01	IGKV2	praluzatamab ravtansine	Humanized	DIVMTQSPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGQGTKLEIK
site429	DG	N	53	H53	H59	True	CDR2	H	10224	10224_seq1	IGHV3-7*01	IGHV3	prezalumab	Human	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS
site430	DG	N+1	54	H54	H62	True	CDR2	H	10224	10224_seq1	IGHV3-7*01	IGHV3	prezalumab	Human	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS
site431	NG	N	54	H54	H62	True	CDR2	H	9723	9723_seq1	IGHV1-3*01	IGHV1	pritoxaximab	Chimeric	QVQLQESGAELVRSGASVRMSCKASGYTFTSYNMHWVKQTPGQGLEWIGYIYPGNGGTNYIQKFKGKAILTADTSSSTAYMQISSLTSEDSAVYFCTRSPSHYSSDPYFDYWGQGTTLTVSS
site432	NG	N+1	55	H55	H63	True	CDR2	H	9723	9723_seq1	IGHV1-3*01	IGHV1	pritoxaximab	Chimeric	QVQLQESGAELVRSGASVRMSCKASGYTFTSYNMHWVKQTPGQGLEWIGYIYPGNGGTNYIQKFKGKAILTADTSSSTAYMQISSLTSEDSAVYFCTRSPSHYSSDPYFDYWGQGTTLTVSS
site433	DG	N	54	H54	H62	False	CDR2	H	11040	11040_seq1	IGHV1-46*01	IGHV1	quetmolimab	Humanized/Chimeric	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVKQAPGQGLEWIGWIYPGDGSPKFNERFKGRTTLTADKSTNTAYMLLSSLRSEDTAVYFCATGPTDGDYFDYWGQGTTVTVSS
site434	DG	N+1	55	H55	H63	True	CDR2	H	11040	11040_seq1	IGHV1-46*01	IGHV1	quetmolimab	Humanized/Chimeric	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVKQAPGQGLEWIGWIYPGDGSPKFNERFKGRTTLTADKSTNTAYMLLSSLRSEDTAVYFCATGPTDGDYFDYWGQGTTVTVSS
site435	DG	N	101	H98	H110	False	CDR3	H	11040	11040_seq1	IGHV1-46*01	IGHV1	quetmolimab	Humanized/Chimeric	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVKQAPGQGLEWIGWIYPGDGSPKFNERFKGRTTLTADKSTNTAYMLLSSLRSEDTAVYFCATGPTDGDYFDYWGQGTTVTVSS
site436	DG	N+1	102	H99	H112	False	CDR3	H	11040	11040_seq1	IGHV1-46*01	IGHV1	quetmolimab	Humanized/Chimeric	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVKQAPGQGLEWIGWIYPGDGSPKFNERFKGRTTLTADKSTNTAYMLLSSLRSEDTAVYFCATGPTDGDYFDYWGQGTTVTVSS
site437	DG	N	54	H54	H62	False	CDR2	H	8998	8998_seq1	IGHV1-3*01	IGHV1	racotumomab	Mouse	QVQLQQSGAELVKPGASVKLSCKASGYTFTSYDINWVRQRPEQGLEWIGWIFPGDGSTKYNEKFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCAREDYYDNSYYFDYWGQGTTLTVSS
site438	DG	N+1	55	H55	H63	True	CDR2	H	8998	8998_seq1	IGHV1-3*01	IGHV1	racotumomab	Mouse	QVQLQQSGAELVKPGASVKLSCKASGYTFTSYDINWVRQRPEQGLEWIGWIFPGDGSTKYNEKFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCAREDYYDNSYYFDYWGQGTTLTVSS
site439	NG	N	53	H53	H59	False	CDR2	H	11242	11242_seq1	IGHV3-7*01	IGHV3	revdofilimab	Chimeric	EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYGMSWVRQAPGKGLELVATINSNGGRTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGITTAYAMDYWGQGTTVTVSS
site440	NG	N+1	54	H54	H62	True	CDR2	H	11242	11242_seq1	IGHV3-7*01	IGHV3	revdofilimab	Chimeric	EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYGMSWVRQAPGKGLELVATINSNGGRTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGITTAYAMDYWGQGTTVTVSS
site441	DG	N	31	L28	L34	False	CDR1	K	11242	11242_seq2	IGKV4-1*01	IGKV4	revdofilimab	Chimeric	DIVMTQSPDSLAVSLGERATINCKASQSVDYDGDSYMHWYQQKPGQPPKLLIYAASILESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPRTFGGGTKVEIK
site442	DG	N+1	32	L29	L35	False	CDR1	K	11242	11242_seq2	IGKV4-1*01	IGKV4	revdofilimab	Chimeric	DIVMTQSPDSLAVSLGERATINCKASQSVDYDGDSYMHWYQQKPGQPPKLLIYAASILESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPRTFGGGTKVEIK
site443	NG	N	100	H96	H108	False	CDR3	H	10175	10175_seq2	IGHV4-39*01	IGHV4	rinucumab	Human	QLQLQESGPGLVKPSETLSLTCTVSGGSITSSSYYWGWIRQPPGKGLEWIGSIYYRGSTNYNPSLKSRVTISVDSSKNQFYLKVSSVTAVDTAVYYCARQNGAARPSWFDPWGQGTLVTVSS
site444	NG	N+1	101	H97	H109	False	CDR3	H	10175	10175_seq2	IGHV4-39*01	IGHV4	rinucumab	Human	QLQLQESGPGLVKPSETLSLTCTVSGGSITSSSYYWGWIRQPPGKGLEWIGSIYYRGSTNYNPSLKSRVTISVDSSKNQFYLKVSSVTAVDTAVYYCARQNGAARPSWFDPWGQGTLVTVSS
site445	NG	N	54	H54	H62	True	CDR2	H	11212	11212_seq1	IGHV1-3*01	IGHV1	ripertamab	Chimeric	QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA
site446	NG	N+1	55	H55	H63	True	CDR2	H	11212	11212_seq1	IGHV1-3*01	IGHV1	ripertamab	Chimeric	QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA
site447	NG	N	54	H54	H62	True	CDR2	H	7609	7609_seq1	IGHV1-3*01	IGHV1	rituximab	Chimeric	QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA
site448	NG	N+1	55	H55	H63	True	CDR2	H	7609	7609_seq1	IGHV1-3*01	IGHV1	rituximab	Chimeric	QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA
site449	DG	N	53	H53	H59	True	CDR2	H	10197	10197_seq1	IGHV3-30*01	IGHV3	rivabazumab	Humanized	EVQLVESGGGVVQPGRSLRLSCAASGFTFSNYPMHWVRQAPGKGLEWVAVISYDGSEKWYADSVKGRFTISRDNSKNTLYLEMNSLRPEDTAVYYCARNRGDIYYDFTYAMDIWGQGTTVTVSS
site450	DG	N+1	54	H54	H62	True	CDR2	H	10197	10197_seq1	IGHV3-30*01	IGHV3	rivabazumab	Humanized	EVQLVESGGGVVQPGRSLRLSCAASGFTFSNYPMHWVRQAPGKGLEWVAVISYDGSEKWYADSVKGRFTISRDNSKNTLYLEMNSLRPEDTAVYYCARNRGDIYYDFTYAMDIWGQGTTVTVSS
site451	DG	N	53	H53	H59	True	CDR2	H	10144	10144_seq1	IGHV3-30*01	IGHV3	rivabazumab pegol	Humanized	EVQLVESGGGVVQPGRSLRLSCAASGFTFSNYPMHWVRQAPGKGLEWVAVISYDGSEKWYADSVKGRFTISRDNSKNTLYLEMNSLRPEDTAVYYCARNRGDIYYDFTYAMDIWGQGTTVTVSS
site452	DG	N+1	54	H54	H62	True	CDR2	H	10144	10144_seq1	IGHV3-30*01	IGHV3	rivabazumab pegol	Humanized	EVQLVESGGGVVQPGRSLRLSCAASGFTFSNYPMHWVRQAPGKGLEWVAVISYDGSEKWYADSVKGRFTISRDNSKNTLYLEMNSLRPEDTAVYYCARNRGDIYYDFTYAMDIWGQGTTVTVSS
site453	DG	N	53	H53	H59	True	CDR2	H	9335	9335_seq2	IGHV3-30*01	IGHV3	roledumab	Human	QVQLVESGGGVVQPGRSLRLSCTASGFTFKNYAMHWVRQAPAKGLEWVATISYDGRNIQYADSVKGRFTFSRDNSQDTLYLQLNSLRPEDTAVYYCARPVRSRWLQLGLEDAFHIWGQGTMVTVSS
site454	DG	N+1	54	H54	H62	True	CDR2	H	9335	9335_seq2	IGHV3-30*01	IGHV3	roledumab	Human	QVQLVESGGGVVQPGRSLRLSCTASGFTFKNYAMHWVRQAPAKGLEWVATISYDGRNIQYADSVKGRFTFSRDNSQDTLYLQLNSLRPEDTAVYYCARPVRSRWLQLGLEDAFHIWGQGTMVTVSS
site455	NG	N	98	H95	H107	False	CDR3	H	10874	10874_seq2	IGHV1-46*01	IGHV1	rolinsatamab	Chimeric	EVQLVQSGAEVKKPGSSVKVSCKASGYTFTTYWMHWVRQAPGQGLEWIGEIDPSDSYSNYNQKFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNGGLGPAWFSYWGQGTLVTVSS
site456	NG	N+1	99	H96	H108	False	CDR3	H	10874	10874_seq2	IGHV1-46*01	IGHV1	rolinsatamab	Chimeric	EVQLVQSGAEVKKPGSSVKVSCKASGYTFTTYWMHWVRQAPGQGLEWIGEIDPSDSYSNYNQKFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNGGLGPAWFSYWGQGTLVTVSS
site457	NG	N	98	H95	H107	False	CDR3	H	10873	10873_seq2	IGHV1-46*01	IGHV1	rolinsatamab talirine	Chimeric	EVQLVQSGAEVKKPGSSVKVSCKASGYTFTTYWMHWVRQAPGQGLEWIGEIDPSDSYSNYNQKFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNGGLGPAWFSYWGQGTLVTVSS
site458	NG	N+1	99	H96	H108	False	CDR3	H	10873	10873_seq2	IGHV1-46*01	IGHV1	rolinsatamab talirine	Chimeric	EVQLVQSGAEVKKPGSSVKVSCKASGYTFTTYWMHWVRQAPGQGLEWIGEIDPSDSYSNYNQKFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNGGLGPAWFSYWGQGTLVTVSS
site459	DG	N	31	L28	L34	False	CDR1	K	10415	10415_seq1	IGKV1-39*01	IGKV1	rosmantuzumab	Humanized	DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISPVQAEDFATYYCQQSNEDPLTFGAGTKLELK
site460	DG	N+1	32	L29	L35	False	CDR1	K	10415	10415_seq1	IGKV1-39*01	IGKV1	rosmantuzumab	Humanized	DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISPVQAEDFATYYCQQSNEDPLTFGAGTKLELK
site461	NG	N	54	H54	H62	False	CDR2	H	10415	10415_seq2	IGHV1-46*01	IGHV1	rosmantuzumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSIHWVRQAPGQGLEWIGYIYPSNGDSGYNQKFKNRVTMTRDTSTSTAYMELSRLRSEDTAVYYCATYFANNFDYWGQGTTLTVSS
site462	NG	N+1	55	H55	H63	True	CDR2	H	10415	10415_seq2	IGHV1-46*01	IGHV1	rosmantuzumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSIHWVRQAPGQGLEWIGYIYPSNGDSGYNQKFKNRVTMTRDTSTSTAYMELSRLRSEDTAVYYCATYFANNFDYWGQGTTLTVSS
site463	NG	N	54	H54	H62	False	CDR2	H	11335	11335_seq1	IGHV1-69-2*01	IGHV1	rosopatamab	Chimeric	EVQLVQSGPEVKKPGATVKISCKTSGYTFTEYTIHWVKQAPGKGLEWIGNINPNNGGTTYNQKFEDKATLTVDKSTDTAYMELSSLRSEDTAVYYCAAGWNFDYWGQGTLLTVSS
site464	NG	N+1	55	H55	H63	True	CDR2	H	11335	11335_seq1	IGHV1-69-2*01	IGHV1	rosopatamab	Chimeric	EVQLVQSGPEVKKPGATVKISCKTSGYTFTEYTIHWVKQAPGKGLEWIGNINPNNGGTTYNQKFEDKATLTVDKSTDTAYMELSSLRSEDTAVYYCAAGWNFDYWGQGTLLTVSS
site465	NG	N	54	H54	H62	False	CDR2	H	11334	11334_seq1	IGHV1-69-2*01	IGHV1	rosopatamab tetraxetan	Chimeric	EVQLVQSGPEVKKPGATVKISCKTSGYTFTEYTIHWVKQAPGKGLEWIGNINPNNGGTTYNQKFEDKATLTVDKSTDTAYMELSSLRSEDTAVYYCAAGWNFDYWGQGTLLTVSS
site466	NG	N+1	55	H55	H63	True	CDR2	H	11334	11334_seq1	IGHV1-69-2*01	IGHV1	rosopatamab tetraxetan	Chimeric	EVQLVQSGPEVKKPGATVKISCKTSGYTFTEYTIHWVKQAPGKGLEWIGNINPNNGGTTYNQKFEDKATLTVDKSTDTAYMELSSLRSEDTAVYYCAAGWNFDYWGQGTLLTVSS
site467	DG	N	53	H53	H59	False	CDR2	H	10213	10213_seq1	IGHV3-48*03	IGHV3	rozanolixizumab	Humanized/Chimeric	EVPLVESGGGLVQPGGSLRLSCAVSGFTFSNYGMVWVRQAPGKGLEWVAYIDSDGDNTYYRDSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCTTGIVRPFLYWGQGTLVTVSS
site468	DG	N+1	54	H54	H62	True	CDR2	H	10213	10213_seq1	IGHV3-48*03	IGHV3	rozanolixizumab	Humanized/Chimeric	EVPLVESGGGLVQPGGSLRLSCAVSGFTFSNYGMVWVRQAPGKGLEWVAYIDSDGDNTYYRDSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCTTGIVRPFLYWGQGTLVTVSS
site469	DG	N	53	H53	H59	True	CDR2	H	10975	10975_seq2	IGHV3-7*01	IGHV3	rozibafusp alfa	Human	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS
site470	DG	N+1	54	H54	H62	True	CDR2	H	10975	10975_seq2	IGHV3-7*01	IGHV3	rozibafusp alfa	Human	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS
site471	NG	N	54	H54	H62	False	CDR2	H	11256	11256_seq1	IGHV1-46*01	IGHV1	sabatolimab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGDIYPGNGDTSYNQKFKGRVTITADKSTSTVYMELSSLRSEDTAVYYCARVGGAFPMDYWGQGTTVTVSS
site472	NG	N+1	55	H55	H63	True	CDR2	H	11256	11256_seq1	IGHV1-46*01	IGHV1	sabatolimab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGDIYPGNGDTSYNQKFKGRVTITADKSTSTVYMELSSLRSEDTAVYYCARVGGAFPMDYWGQGTTVTVSS
site473	DG	N	53	H53	H59	True	CDR2	H	9182	9182_seq1	IGHV3-7*01	IGHV3	secukinumab	Human	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSS
site474	DG	N+1	54	H54	H62	True	CDR2	H	9182	9182_seq1	IGHV3-7*01	IGHV3	secukinumab	Human	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSS
site475	NG	N	106	H100C	H112C	False	CDR3	H	10523	10523_seq2	IGHV1-2*02	IGHV1	selicrelumab	Human	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPDSGGTNYAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARDQPLGYCTNGVCSYFDYWGQGTLVTVSS
site476	NG	N+1	107	H100D	H112B	False	CDR3	H	10523	10523_seq2	IGHV1-2*02	IGHV1	selicrelumab	Human	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPDSGGTNYAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARDQPLGYCTNGVCSYFDYWGQGTLVTVSS
site477	NG	N	32	L28	L34	False	CDR1	K	11024	11024_seq2	IGKV2-29*02	IGKV2	semorinemab	Humanized/Chimeric	DDVLTQTPLSLPVTPGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLVPWTFGQGTKVEIK
site478	NG	N+1	33	L29	L35	True	CDR1	K	11024	11024_seq2	IGKV2-29*02	IGKV2	semorinemab	Humanized/Chimeric	DDVLTQTPLSLPVTPGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLVPWTFGQGTKVEIK
site479	NG	N	54	H54	H59	False	CDR2	H	10960	10960_seq1	IGHV4-30-4*01	IGHV4	serclutamab	Humanized/Chimeric	EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS
site480	NG	N+1	55	H55	H63	True	CDR2	H	10960	10960_seq1	IGHV4-30-4*01	IGHV4	serclutamab	Humanized/Chimeric	EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS
site481	NG	N	54	H54	H59	False	CDR2	H	10959	10959_seq1	IGHV4-30-4*01	IGHV4	serclutamab talirine	Humanized/Chimeric	EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS
site482	NG	N+1	55	H55	H63	True	CDR2	H	10959	10959_seq1	IGHV4-30-4*01	IGHV4	serclutamab talirine	Humanized/Chimeric	EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS
site483	DG	N	53	H53	H59	True	CDR2	H	10539	10539_seq1	IGHV3-74*01	IGHV3	setrusumab	Human	QVQLVESGGGLVQPGGSLRLSCAASGFTFRSHWLSWVRQAPGKGLEWVSNINYDGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDTYLHFDYWGQGTLVTVSS
site484	DG	N+1	54	H54	H62	True	CDR2	H	10539	10539_seq1	IGHV3-74*01	IGHV3	setrusumab	Human	QVQLVESGGGLVQPGGSLRLSCAASGFTFRSHWLSWVRQAPGKGLEWVSNINYDGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDTYLHFDYWGQGTLVTVSS
site485	NG	N	54	H54	H62	True	CDR2	H	9135	9135_seq2	IGHV1-18*01	IGHV1	sifalimumab	Human	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYSISWVRQAPGQGLEWMGWISVYNGNTNYAQKFQGRVTMTTDTSTSTAYLELRSLRSDDTAVYYCARDPIAAGYWGQGTLVTVSS
site486	NG	N+1	55	H55	H63	True	CDR2	H	9135	9135_seq2	IGHV1-18*01	IGHV1	sifalimumab	Human	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYSISWVRQAPGQGLEWMGWISVYNGNTNYAQKFQGRVTMTTDTSTSTAYLELRSLRSDDTAVYYCARDPIAAGYWGQGTLVTVSS
site487	NG	N	32	L28	L34	False	CDR1	K	9626	9626_seq1	IGKV2D-29*02	IGKV2D	simtuzumab	Humanized	DIVMTQTPLSLSVTPGQPASISCRSSKSLLHSNGNTYLYWFLQKPGQSPQFLIYRMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPYTFGGGTKVEIK
site488	NG	N+1	33	L29	L35	True	CDR1	K	9626	9626_seq1	IGKV2D-29*02	IGKV2D	simtuzumab	Humanized	DIVMTQTPLSLSVTPGQPASISCRSSKSLLHSNGNTYLYWFLQKPGQSPQFLIYRMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPYTFGGGTKVEIK
site489	DG	N	53	H53	H59	True	CDR2	H	10468	10468_seq2	IGHV3-33*01	IGHV3	sirtratumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNQYYADSVKGRFTISRDNSKNTLFLQMHSLRAEDTAVYYCARGLTSGRYGMDVWGQGTTVTVSS
site490	DG	N+1	54	H54	H62	True	CDR2	H	10468	10468_seq2	IGHV3-33*01	IGHV3	sirtratumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNQYYADSVKGRFTISRDNSKNTLFLQMHSLRAEDTAVYYCARGLTSGRYGMDVWGQGTTVTVSS
site491	DG	N	53	H53	H59	True	CDR2	H	10467	10467_seq2	IGHV3-33*01	IGHV3	sirtratumab vedotin	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNQYYADSVKGRFTISRDNSKNTLFLQMHSLRAEDTAVYYCARGLTSGRYGMDVWGQGTTVTVSS
site492	DG	N+1	54	H54	H62	True	CDR2	H	10467	10467_seq2	IGHV3-33*01	IGHV3	sirtratumab vedotin	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNQYYADSVKGRFTISRDNSKNTLFLQMHSLRAEDTAVYYCARGLTSGRYGMDVWGQGTTVTVSS
site493	DG	N	32	L28	L34	True	CDR1	K	9097	9097_seq2	IGKV2-30*01	IGKV2	solanezumab	Humanized	DVVMTQSPLSLPVTLGQPASISCRSSQSLIYSDGNAYLHWFLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK
site494	DG	N+1	33	L29	L35	True	CDR1	K	9097	9097_seq2	IGKV2-30*01	IGKV2	solanezumab	Humanized	DVVMTQSPLSLPVTLGQPASISCRSSQSLIYSDGNAYLHWFLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK
site495	NG	N	54	H54	H62	True	CDR2	H	10291	10291_seq2	IGHV1-3*01	IGHV1	tabituximab	Chimeric	EVQLQQSGAELVKPGASVKLSCTASGFNINDTYMHWVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCARGARGSRFAYWGQGTLVTVSA
site496	NG	N+1	55	H55	H63	True	CDR2	H	10291	10291_seq2	IGHV1-3*01	IGHV1	tabituximab	Chimeric	EVQLQQSGAELVKPGASVKLSCTASGFNINDTYMHWVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCARGARGSRFAYWGQGTLVTVSA
site497	NG	N	54	H54	H62	True	CDR2	H	10232	10232_seq2	IGHV1-3*01	IGHV1	tabituximab barzuxetan	Chimeric	EVQLQQSGAELVKPGASVKLSCTASGFNINDTYMHWVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCARGARGSRFAYWGQGTLVTVSA
site498	NG	N+1	55	H55	H63	True	CDR2	H	10232	10232_seq2	IGHV1-3*01	IGHV1	tabituximab barzuxetan	Chimeric	EVQLQQSGAELVKPGASVKLSCTASGFNINDTYMHWVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCARGARGSRFAYWGQGTLVTVSA
site499	DG	N	99	H96	H108	False	CDR3	H	8651	8651_seq2	IGHV1-69*01	IGHV1	tadocizumab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYAFTNYLIEWVRQAPGQGLEWIGVIYPGSGGTNYNEKFKGRVTLTVDESTNTAYMELSSLRSEDTAVYFCARRDGNYGWFAYWGQGTLVTVSS
site500	DG	N+1	100	H97	H109	False	CDR3	H	8651	8651_seq2	IGHV1-69*01	IGHV1	tadocizumab	Humanized	QVQLVQSGAEVKKPGSSVKVSCKASGYAFTNYLIEWVRQAPGQGLEWIGVIYPGSGGTNYNEKFKGRVTLTVDESTNTAYMELSSLRSEDTAVYFCARRDGNYGWFAYWGQGTLVTVSS
site501	DG	N	55	H55	H63	False	CDR2	H	10835	10835_seq1	IGHV1-3*01	IGHV1	tafasitamab	Humanized	EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS
site502	DG	N+1	56	H56	H64	False	CDR2	H	10835	10835_seq1	IGHV1-3*01	IGHV1	tafasitamab	Humanized	EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS
site503	NG	N	32	L28	L34	False	CDR1	K	10835	10835_seq2	IGKV3-11*01	IGKV3	tafasitamab	Humanized	DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK
site504	NG	N+1	33	L29	L35	False	CDR1	K	10835	10835_seq2	IGKV3-11*01	IGKV3	tafasitamab	Humanized	DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK
site505	NG	N	54	H54	H62	False	CDR2	H	10508	10508_seq1	IGHV5-10-1*04	IGHV5	talacotuzumab	Humanized	EVQLVQSGAEVKKPGESLKISCKGSGYSFTDYYMKWARQMPGKGLEWMGDIIPSNGATFYNQKFKGQVTISADKSISTTYLQWSSLKASDTAMYYCARSHLLRASWFAYWGQGTMVTVSS
site506	NG	N+1	55	H55	H63	False	CDR2	H	10508	10508_seq1	IGHV5-10-1*04	IGHV5	talacotuzumab	Humanized	EVQLVQSGAEVKKPGESLKISCKGSGYSFTDYYMKWARQMPGKGLEWMGDIIPSNGATFYNQKFKGQVTISADKSISTTYLQWSSLKASDTAMYYCARSHLLRASWFAYWGQGTMVTVSS
site507	DG	N	53	H54	H59	False	CDR2	H	8941	8941_seq1	IGHV4-38-2*02	IGHV4	tanezumab	Humanized	QVQLQESGPGLVKPSETLSLTCTVSGFSLIGYDLNWIRQPPGKGLEWIGIIWGDGTTDYNSAVKSRVTISKDTSKNQFSLKLSSVTAADTAVYYCARGGYWYATSYYFDYWGQGTLVTVSS
site508	DG	N+1	54	H55	H63	True	CDR2	H	8941	8941_seq1	IGHV4-38-2*02	IGHV4	tanezumab	Humanized	QVQLQESGPGLVKPSETLSLTCTVSGFSLIGYDLNWIRQPPGKGLEWIGIIWGDGTTDYNSAVKSRVTISKDTSKNQFSLKLSSVTAADTAVYYCARGGYWYATSYYFDYWGQGTLVTVSS
site509	NG	N	53	H54	H59	False	CDR2	H	10420	10420_seq1	IGHV4-34*09	IGHV4	tavolimab	Humanized/Chimeric	QVQLQESGPGLVKPSQTLSLTCAVYGGSFSSGYWNWIRKHPGKGLEYIGYISYNGITYHNPSLKSRITINRDTSKNQYSLQLNSVTPEDTAVYYCARYKYDYDGGHAMDYWGQGTLVTVSS
site510	NG	N+1	54	H55	H63	True	CDR2	H	10420	10420_seq1	IGHV4-34*09	IGHV4	tavolimab	Humanized/Chimeric	QVQLQESGPGLVKPSQTLSLTCAVYGGSFSSGYWNWIRKHPGKGLEYIGYISYNGITYHNPSLKSRITINRDTSKNQYSLQLNSVTPEDTAVYYCARYKYDYDGGHAMDYWGQGTLVTVSS
site511	DG	N	102	H100	H111A	False	CDR3	H	10420	10420_seq1	IGHV4-34*09	IGHV4	tavolimab	Humanized/Chimeric	QVQLQESGPGLVKPSQTLSLTCAVYGGSFSSGYWNWIRKHPGKGLEYIGYISYNGITYHNPSLKSRITINRDTSKNQYSLQLNSVTPEDTAVYYCARYKYDYDGGHAMDYWGQGTLVTVSS
site512	DG	N+1	103	H100A	H112A	False	CDR3	H	10420	10420_seq1	IGHV4-34*09	IGHV4	tavolimab	Humanized/Chimeric	QVQLQESGPGLVKPSQTLSLTCAVYGGSFSSGYWNWIRKHPGKGLEYIGYISYNGITYHNPSLKSRITINRDTSKNQYSLQLNSVTPEDTAVYYCARYKYDYDGGHAMDYWGQGTLVTVSS
site513	DG	N	102	H98	H113	False	CDR3	H	11273	11273_seq1	IGHV2-70*10	IGHV2	telazorlimab	Humanized	QVTLKESGPALVKPTQTLTLTCSFSGFSLSTSGMGVGWIRQPPGKALEWIAHIWWDDDKYYNTALKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIDWDGFAYWGQGTLVTVSS
site514	DG	N+1	103	H99	H114	False	CDR3	H	11273	11273_seq1	IGHV2-70*10	IGHV2	telazorlimab	Humanized	QVTLKESGPALVKPTQTLTLTCSFSGFSLSTSGMGVGWIRQPPGKALEWIAHIWWDDDKYYNTALKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIDWDGFAYWGQGTLVTVSS
site515	NG	N	54	H54	H62	False	CDR2	H	10366	10366_seq1	IGHV1-2*02	IGHV1	telisotuzumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYIFTAYTMHWVRQAPGQGLEWMGWIKPNNGLANYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSEITTEFDYWGQGTLVTVSS
site516	NG	N+1	55	H55	H63	True	CDR2	H	10366	10366_seq1	IGHV1-2*02	IGHV1	telisotuzumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYIFTAYTMHWVRQAPGQGLEWMGWIKPNNGLANYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSEITTEFDYWGQGTLVTVSS
site517	NG	N	54	H54	H62	False	CDR2	H	10365	10365_seq1	IGHV1-2*02	IGHV1	telisotuzumab vedotin	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYIFTAYTMHWVRQAPGQGLEWMGWIKPNNGLANYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSEITTEFDYWGQGTLVTVSS
site518	NG	N+1	55	H55	H63	True	CDR2	H	10365	10365_seq1	IGHV1-2*02	IGHV1	telisotuzumab vedotin	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYIFTAYTMHWVRQAPGQGLEWMGWIKPNNGLANYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSEITTEFDYWGQGTLVTVSS
site519	NG	N	32	L28	L34	True	CDR1	K	8832	8832_seq1	IGKV2-28*01	IGKV2	tenatumomab	Mouse	DIVMTQAAPSVPVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPLTFGAGTKLELK
site520	NG	N+1	33	L29	L35	True	CDR1	K	8832	8832_seq1	IGKV2-28*01	IGKV2	tenatumomab	Mouse	DIVMTQAAPSVPVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPLTFGAGTKLELK
site521	NG	N	54	H54	H62	True	CDR2	H	8832	8832_seq2	IGHV1-3*01	IGHV1	tenatumomab	Mouse	EIQLQQSGPELVKPGASVKVSCKASGYAFTSYNMYWVKQSHGKSLEWIGYIDPYNGVTSYNQKFKGKATLTVDKSSSTAYMHLNSLTSEDSAVYYCARGGGSIYYAMDYWGQGTSVTVSS
site522	NG	N+1	55	H55	H63	True	CDR2	H	8832	8832_seq2	IGHV1-3*01	IGHV1	tenatumomab	Mouse	EIQLQQSGPELVKPGASVKVSCKASGYAFTSYNMYWVKQSHGKSLEWIGYIDPYNGVTSYNQKFKGKATLTVDKSSSTAYMHLNSLTSEDSAVYYCARGGGSIYYAMDYWGQGTSVTVSS
site523	DG	N	53	H53	H59	True	CDR2	H	9107	9107_seq2	IGHV3-33*01	IGHV3	teprotumumab	Human	QVELVESGGGVVQPGRSQRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWFDGSSTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARELGRRYFDLWGRGTLVSVSS
site524	DG	N+1	54	H54	H62	True	CDR2	H	9107	9107_seq2	IGHV3-33*01	IGHV3	teprotumumab	Human	QVELVESGGGVVQPGRSQRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWFDGSSTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARELGRRYFDLWGRGTLVSVSS
site525	DG	N	53	H53	H59	True	CDR2	H	10172	10172_seq2	IGHV3-33*01	IGHV3	tezepelumab	Human	QMQLVESGGGVVQPGRSLRLSCAASGFTFRTYGMHWVRQAPGKGLEWVAVIWYDGSNKHYADSVKGRFTITRDNSKNTLNLQMNSLRAEDTAVYYCARAPQWELVHEAFDIWGQGTMVTVSS
site526	DG	N+1	54	H54	H62	True	CDR2	H	10172	10172_seq2	IGHV3-33*01	IGHV3	tezepelumab	Human	QMQLVESGGGVVQPGRSLRLSCAASGFTFRTYGMHWVRQAPGKGLEWVAVIWYDGSNKHYADSVKGRFTITRDNSKNTLNLQMNSLRAEDTAVYYCARAPQWELVHEAFDIWGQGTMVTVSS
site527	NG	N	54	H54	H62	True	CDR2	H	11267	11267_seq1	IGHV1-3*01	IGHV1	tilogotamab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTHMHWVRQAPGQRLEWIGRIDPANGNTEYDQKFQGRVTITVDTSASTAYMELSSLRSEDTAVYYCARWGTNVYFAYWGQGTLVTVSS
site528	NG	N+1	55	H55	H63	True	CDR2	H	11267	11267_seq1	IGHV1-3*01	IGHV1	tilogotamab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTHMHWVRQAPGQRLEWIGRIDPANGNTEYDQKFQGRVTITVDTSASTAYMELSSLRSEDTAVYYCARWGTNVYFAYWGQGTLVTVSS
site529	NG	N	32	L28	L34	False	CDR1	K	11122	11122_seq1	IGKV1-39*01	IGKV1	tilvestamab	Humanized	DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGIPYLHWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCSQGTHVPPTFGQGTKVEIK
site530	NG	N+1	33	L29	L35	False	CDR1	K	11122	11122_seq1	IGKV1-39*01	IGKV1	tilvestamab	Humanized	DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGIPYLHWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCSQGTHVPPTFGQGTKVEIK
site531	NG	N	54	H54	H62	False	CDR2	H	10335	10335_seq1	IGHV3-66*01	IGHV3	timigutuzumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site532	NG	N+1	55	H55	H63	True	CDR2	H	10335	10335_seq1	IGHV3-66*01	IGHV3	timigutuzumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site533	DG	N	101	H98	H110	False	CDR3	H	10335	10335_seq1	IGHV3-66*01	IGHV3	timigutuzumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site534	DG	N+1	102	H99	H111	False	CDR3	H	10335	10335_seq1	IGHV3-66*01	IGHV3	timigutuzumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site535	DG	N	53	H53	H59	True	CDR2	H	10248	10248_seq2	IGHV3-30*01	IGHV3	timolumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFFSYAMHWVRQTPGKGLEWVAVIWFDGSNENYVDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDAWSYFDYWGQGTLVTVSS
site536	DG	N+1	54	H54	H62	True	CDR2	H	10248	10248_seq2	IGHV3-30*01	IGHV3	timolumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFFSYAMHWVRQTPGKGLEWVAVIWFDGSNENYVDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDAWSYFDYWGQGTLVTVSS
site537	DG	N	53	H54	H59	False	CDR2	H	10553	10553_seq2	IGHV4-4*08	IGHV4	tislelizumab	Humanized	QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGVHWIRQPPGKGLEWIGVIYADGSTNYNPSLKSRVTISKDTSKNQVSLKLSSVTAADTAVYYCARAYGNYWYIDVWGQGTTVTVSS
site538	DG	N+1	54	H55	H63	True	CDR2	H	10553	10553_seq2	IGHV4-4*08	IGHV4	tislelizumab	Humanized	QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGVHWIRQPPGKGLEWIGVIYADGSTNYNPSLKSRVTISKDTSKNQVSLKLSSVTAADTAVYYCARAYGNYWYIDVWGQGTTVTVSS
site539	DG	N	107	H100D	H113	True	CDR3	H	11776	11776_seq2	IGHV1-58*01	IGHV1	tixagevimab	Human	QMQLVQSGPEVKKPGTSVKVSCKASGFTFMSSAVQWVRQARGQRLEWIGWIVIGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPYCSSISCNDGFDIWGQGTMVTVSS
site540	DG	N+1	108	H100E	H114	False	CDR3	H	11776	11776_seq2	IGHV1-58*01	IGHV1	tixagevimab	Human	QMQLVQSGPEVKKPGTSVKVSCKASGFTFMSSAVQWVRQARGQRLEWIGWIVIGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPYCSSISCNDGFDIWGQGTMVTVSS
site541	DG	N	54	H54	H62	False	CDR2	H	11044	11044_seq2	IGHV1-3*01	IGHV1	tomaralimab	Chimeric	EVQLVQSGSELKKPGASVKLSCKASGFTFTTYGINWVRQAPGQGLEWIGWIYPRDGSTNFNENFKDRATITVDTSASTAYMELSSLRSEDTAVYFCARLTGGTFLDYWGQGTTVTVSS
site542	DG	N+1	55	H55	H63	True	CDR2	H	11044	11044_seq2	IGHV1-3*01	IGHV1	tomaralimab	Chimeric	EVQLVQSGSELKKPGASVKLSCKASGFTFTTYGINWVRQAPGQGLEWIGWIYPRDGSTNFNENFKDRATITVDTSASTAYMELSSLRSEDTAVYFCARLTGGTFLDYWGQGTTVTVSS
site543	NG	N	32	L28	L34	False	CDR1	K	10820	10820_seq2	IGKV2-30*02	IGKV2	toripalimab	Humanized	DVVMTQSPLSLPVTLGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPLTFGQGTKLEIK
site544	NG	N+1	33	L29	L35	True	CDR1	K	10820	10820_seq2	IGKV2-30*02	IGKV2	toripalimab	Humanized	DVVMTQSPLSLPVTLGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPLTFGQGTKLEIK
site545	NG	N	96	L95A	L113	False	CDR3	L	9757	9757_seq2	IGLV1-44*01	IGLV1	tosatoxumab	Human	QSVLTQSPSASGTPGQRVTISCSGGSSNIGSNTVNWYQQFPGAAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGLYVFGTGTKVTVL
site546	NG	N+1	97	L95B	L114	False	CDR3	L	9757	9757_seq2	IGLV1-44*01	IGLV1	tosatoxumab	Human	QSVLTQSPSASGTPGQRVTISCSGGSSNIGSNTVNWYQQFPGAAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGLYVFGTGTKVTVL
site547	DG	N	49	L51	L57	True	CDR2	L	9235	9235_seq1	IGLV3-21*01	IGLV3	tralokinumab	Human	SYVLTQPPSVSVAPGKTARITCGGNIIGSKLVHWYQQKPGQAPVLVIYDDGDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDTGSDPVVFGGGTKLTVL
site548	DG	N+1	50	L52	L65	False	CDR2	L	9235	9235_seq1	IGLV3-21*01	IGLV3	tralokinumab	Human	SYVLTQPPSVSVAPGKTARITCGGNIIGSKLVHWYQQKPGQAPVLVIYDDGDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDTGSDPVVFGGGTKLTVL
site549	NG	N	54	H54	H62	True	CDR2	H	9235	9235_seq2	IGHV1-18*01	IGHV1	tralokinumab	Human	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLSWVRQAPGQGLEWMGWISANNGDTNYGQEFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDSSSSWARWFFDLWGRGTLVTVSS
site550	NG	N+1	55	H55	H63	True	CDR2	H	9235	9235_seq2	IGHV1-18*01	IGHV1	tralokinumab	Human	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLSWVRQAPGQGLEWMGWISANNGDTNYGQEFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDSSSSWARWFFDLWGRGTLVTVSS
site551	NG	N	54	H54	H62	False	CDR2	H	7637	7637_seq1	IGHV3-66*01	IGHV3	trastuzumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site552	NG	N+1	55	H55	H63	True	CDR2	H	7637	7637_seq1	IGHV3-66*01	IGHV3	trastuzumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site553	DG	N	101	H98	H110	False	CDR3	H	7637	7637_seq1	IGHV3-66*01	IGHV3	trastuzumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site554	DG	N+1	102	H99	H111	False	CDR3	H	7637	7637_seq1	IGHV3-66*01	IGHV3	trastuzumab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site555	NG	N	54	H54	H62	False	CDR2	H	9956	9956_seq1	IGHV3-66*01	IGHV3	trastuzumab beta	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site556	NG	N+1	55	H55	H63	True	CDR2	H	9956	9956_seq1	IGHV3-66*01	IGHV3	trastuzumab beta	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site557	DG	N	101	H98	H110	False	CDR3	H	9956	9956_seq1	IGHV3-66*01	IGHV3	trastuzumab beta	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site558	DG	N+1	102	H99	H111	False	CDR3	H	9956	9956_seq1	IGHV3-66*01	IGHV3	trastuzumab beta	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site559	NG	N	54	H54	H62	False	CDR2	H	10516	10516_seq1	IGHV3-66*01	IGHV3	trastuzumab deruxtecan	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site560	NG	N+1	55	H55	H63	True	CDR2	H	10516	10516_seq1	IGHV3-66*01	IGHV3	trastuzumab deruxtecan	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site561	DG	N	101	H98	H110	False	CDR3	H	10516	10516_seq1	IGHV3-66*01	IGHV3	trastuzumab deruxtecan	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site562	DG	N+1	102	H99	H111	False	CDR3	H	10516	10516_seq1	IGHV3-66*01	IGHV3	trastuzumab deruxtecan	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site563	NG	N	54	H54	H62	False	CDR2	H	10273	10273_seq1	IGHV3-66*01	IGHV3	trastuzumab duocarmazine	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site564	NG	N+1	55	H55	H63	True	CDR2	H	10273	10273_seq1	IGHV3-66*01	IGHV3	trastuzumab duocarmazine	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site565	DG	N	101	H98	H110	False	CDR3	H	10273	10273_seq1	IGHV3-66*01	IGHV3	trastuzumab duocarmazine	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site566	DG	N+1	102	H99	H111	False	CDR3	H	10273	10273_seq1	IGHV3-66*01	IGHV3	trastuzumab duocarmazine	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site567	NG	N	54	H54	H62	False	CDR2	H	9295	9295_seq1	IGHV3-66*01	IGHV3	trastuzumab emtansine	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site568	NG	N+1	55	H55	H63	True	CDR2	H	9295	9295_seq1	IGHV3-66*01	IGHV3	trastuzumab emtansine	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site569	DG	N	101	H98	H110	False	CDR3	H	9295	9295_seq1	IGHV3-66*01	IGHV3	trastuzumab emtansine	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site570	DG	N+1	102	H99	H111	False	CDR3	H	9295	9295_seq1	IGHV3-66*01	IGHV3	trastuzumab emtansine	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
site571	DG	N	53	H53	H59	True	CDR2	H	8716	8716_seq2	IGHV3-33*01	IGHV3	tremelimumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS
site572	DG	N+1	54	H54	H62	True	CDR2	H	8716	8716_seq2	IGHV3-33*01	IGHV3	tremelimumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS
site573	DG	N	98	H95	H107	False	CDR3	H	10087	10087_seq2	IGHV3-23*01	IGHV3	trevogrumab	Human	EVQVLESGGDLVQPGGSLRLSCAASGFTFSAYAMTWVRQAPGKGLEWVSAISGSGGSAYYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAKDGAWKMSGLDVWGQGTTVIVSS
site574	DG	N+1	99	H96	H108	False	CDR3	H	10087	10087_seq2	IGHV3-23*01	IGHV3	trevogrumab	Human	EVQVLESGGDLVQPGGSLRLSCAASGFTFSAYAMTWVRQAPGKGLEWVSAISGSGGSAYYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAKDGAWKMSGLDVWGQGTTVIVSS
site575	NG	N	54	H54	H62	True	CDR2	H	9334	9334_seq2	IGHV1-3*01	IGHV1	ublituximab	Chimeric	QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGGIYPGNGDTSYNQKFKGKATLTVGKSSSTAYMQLSSLTSEDSAVYFCARYDYNYAMDYWGQGTSVTVSS
site576	NG	N+1	55	H55	H63	True	CDR2	H	9334	9334_seq2	IGHV1-3*01	IGHV1	ublituximab	Chimeric	QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGGIYPGNGDTSYNQKFKGKATLTVGKSSSTAYMQLSSLTSEDSAVYFCARYDYNYAMDYWGQGTSVTVSS
site577	NG	N	54	H54	H62	False	CDR2	H	11344	11344_seq1	IGHV1-46*01	IGHV1	upifitamab	Humanized/Chimeric	QVQLVQSGAEVVKPGASVKMSCKASGYTFTGYNIHWVKQAPGQGLEWIGAIYPGNGDTSYKQKFRGRATLTADTSTSTVYMELSSLRSEDSAVYYCARGETARATFAYWGQGTLVTVSS
site578	NG	N+1	55	H55	H63	True	CDR2	H	11344	11344_seq1	IGHV1-46*01	IGHV1	upifitamab	Humanized/Chimeric	QVQLVQSGAEVVKPGASVKMSCKASGYTFTGYNIHWVKQAPGQGLEWIGAIYPGNGDTSYKQKFRGRATLTADTSTSTVYMELSSLRSEDSAVYYCARGETARATFAYWGQGTLVTVSS
site579	DG	N	98	H95	H107	False	CDR3	H	11236	11236_seq1	IGHV4-4*02	IGHV4	urabrelimab	Human	QVQLQESGPGLVKPSGTLSLTCAVSGVSIRSINWWNWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLNSVTAADTAVYYCARDGGIAVTDYYYYGLDVWGQGTTVTVSS
site580	DG	N+1	99	H96	H108	False	CDR3	H	11236	11236_seq1	IGHV4-4*02	IGHV4	urabrelimab	Human	QVQLQESGPGLVKPSGTLSLTCAVSGVSIRSINWWNWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLNSVTAADTAVYYCARDGGIAVTDYYYYGLDVWGQGTTVTVSS
site581	DG	N	54	H54	H62	False	CDR2	H	10242	10242_seq2	IGHV1-18*01	IGHV1	vadastuximab	Chimeric	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYDINWVRQAPGQGLEWIGWIYPGDGSTKYNEKFKAKATLTADTSTSTAYMELRSLRSDDTAVYYCASGYEDAMDYWGQGTTVTVSS
site582	DG	N+1	55	H55	H63	True	CDR2	H	10242	10242_seq2	IGHV1-18*01	IGHV1	vadastuximab	Chimeric	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYDINWVRQAPGQGLEWIGWIYPGDGSTKYNEKFKAKATLTADTSTSTAYMELRSLRSDDTAVYYCASGYEDAMDYWGQGTTVTVSS
site583	DG	N	54	H54	H62	False	CDR2	H	9983	9983_seq2	IGHV1-18*01	IGHV1	vadastuximab talirine	Chimeric	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYDINWVRQAPGQGLEWIGWIYPGDGSTKYNEKFKAKATLTADTSTSTAYMELRSLRSDDTAVYYCASGYEDAMDYWGQGTTVTVSS
site584	DG	N+1	55	H55	H63	True	CDR2	H	9983	9983_seq2	IGHV1-18*01	IGHV1	vadastuximab talirine	Chimeric	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYDINWVRQAPGQGLEWIGWIYPGDGSTKYNEKFKAKATLTADTSTSTAYMELRSLRSDDTAVYYCASGYEDAMDYWGQGTTVTVSS
site585	DG	N	54	H54	H62	False	CDR2	H	10501	10501_seq1	IGHV1-3*01	IGHV1	valanafusp alfa	Chimeric	QVQLQQSGPELVKPGALVKISCKASGYTFTNYDIHWVKQRPGQGLEWIGWIYPGDGSTKYNEKFKGKATLTADKSSSTAYMHLSSLTSEKSAVYFCAREWAYWGQGTLVTVSA
site586	DG	N+1	55	H55	H63	True	CDR2	H	10501	10501_seq1	IGHV1-3*01	IGHV1	valanafusp alfa	Chimeric	QVQLQQSGPELVKPGALVKISCKASGYTFTNYDIHWVKQRPGQGLEWIGWIYPGDGSTKYNEKFKGKATLTADKSSSTAYMHLSSLTSEKSAVYFCAREWAYWGQGTLVTVSA
site587	DG	N	53	H53	H59	False	CDR2	H	9779	9779_seq1	IGHV3-23*04	IGHV3	vantictumab	Human	EVQLVESGGGLVQPGGSLRLSCAASGFTFSHYTLSWVRQAPGKGLEWVSVISGDGSYTYYADSVKGRFTISSDNSKNTLYLQMNSLRAEDTAVYYCARNFIKYVFANWGQGTLVTVSS
site588	DG	N+1	54	H54	H62	True	CDR2	H	9779	9779_seq1	IGHV3-23*04	IGHV3	vantictumab	Human	EVQLVESGGGLVQPGGSLRLSCAASGFTFSHYTLSWVRQAPGKGLEWVSVISGDGSYTYYADSVKGRFTISSDNSKNTLYLQMNSLRAEDTAVYYCARNFIKYVFANWGQGTLVTVSS
site589	NG	N	110	H100G	H113	False	CDR3	H	10427	10427_seq2	IGHV1-24*01	IGHV1	varisacumab	Human	QVQLVQSGAEVKKPGASVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGRSMVRGVIIPFNGMDVWGQGTTVTVSS
site590	NG	N+1	111	H100H	H114	True	CDR3	H	10427	10427_seq2	IGHV1-24*01	IGHV1	varisacumab	Human	QVQLVQSGAEVKKPGASVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGRSMVRGVIIPFNGMDVWGQGTTVTVSS
site591	DG	N	54	H54	H62	True	CDR2	H	10427	10427_seq2	IGHV1-24*01	IGHV1	varisacumab	Human	QVQLVQSGAEVKKPGASVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGRSMVRGVIIPFNGMDVWGQGTTVTVSS
site592	DG	N+1	55	H55	H63	True	CDR2	H	10427	10427_seq2	IGHV1-24*01	IGHV1	varisacumab	Human	QVQLVQSGAEVKKPGASVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGRSMVRGVIIPFNGMDVWGQGTTVTVSS
site593	DG	N	53	H53	H59	True	CDR2	H	9933	9933_seq2	IGHV3-33*01	IGHV3	varlilumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYDMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSGNWGFFDYWGQGTLVTVSS
site594	DG	N+1	54	H54	H62	True	CDR2	H	9933	9933_seq2	IGHV3-33*01	IGHV3	varlilumab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYDMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSGNWGFFDYWGQGTLVTVSS
site595	DG	N	99	H97	H109	False	CDR3	H	9439	9439_seq2	IGHV4-4*08	IGHV4	vatelizumab	Humanized	QVQLQESGPGLVKPSETLSLTCTVSGFSLTNYGIHWIRQPPGKGLEWLGVIWARGFTNYNSALMSRLTISKDNSKNQVSLKLSSVTAADTAVYYCARANDGVYYAMDYWGQGTLVTVSS
site596	DG	N+1	100	H98	H110	False	CDR3	H	9439	9439_seq2	IGHV4-4*08	IGHV4	vatelizumab	Humanized	QVQLQESGPGLVKPSETLSLTCTVSGFSLTNYGIHWIRQPPGKGLEWLGVIWARGFTNYNSALMSRLTISKDNSKNQVSLKLSSVTAADTAVYYCARANDGVYYAMDYWGQGTLVTVSS
site597	DG	N	101	H98	H110	False	CDR3	H	9093	9093_seq2	IGHV1-3*01	IGHV1	vedolizumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSS
site598	DG	N+1	102	H99	H111	False	CDR3	H	9093	9093_seq2	IGHV1-3*01	IGHV1	vedolizumab	Humanized	QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSS
site599	NG	N	54	H54	H62	False	CDR2	H	8932	8932_seq2	IGHV1-46*01	IGHV1	veltuzumab	Humanized	QVQLQQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVKQAPGQGLEWIGAIYPGNGDTSYNQKFKGKATLTADESTNTAYMELSSLRSEDTAFYYCARSTYYGGDWYFDVWGQGTTVTVSS
site600	NG	N+1	55	H55	H63	True	CDR2	H	8932	8932_seq2	IGHV1-46*01	IGHV1	veltuzumab	Humanized	QVQLQQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVKQAPGQGLEWIGAIYPGNGDTSYNQKFKGKATLTADESTNTAYMELSSLRSEDTAFYYCARSTYYGGDWYFDVWGQGTTVTVSS
site601	NG	N	54	H54	H62	False	CDR2	H	11021	11021_seq2	IGHV1-46*01	IGHV1	vibecotamab	Chimeric	QVQLQQSGAEVKKPGASVKVSCKASGYTFTDYYMKWVKQSHGKSLEWMGDIIPSNGATFYNQKFKGKATLTVDRSTSTAYMELSSLRSEDTAVYYCARSHLLRASWFAYWGQGTLVTVSS
site602	NG	N+1	55	H55	H63	True	CDR2	H	11021	11021_seq2	IGHV1-46*01	IGHV1	vibecotamab	Chimeric	QVQLQQSGAEVKKPGASVKVSCKASGYTFTDYYMKWVKQSHGKSLEWMGDIIPSNGATFYNQKFKGKATLTVDRSTSTAYMELSSLRSEDTAVYYCARSHLLRASWFAYWGQGTLVTVSS
site603	DG	N	55	H55	H63	False	CDR2	H	11178	11178_seq2	IGHV1-69*02	IGHV1	vibostolimab	Humanized	EVQLVQSGAEVKKPGSSVKVSCKASGYTFSSYVMHWVRQAPGQGLEWIGYIDPYNDGAKYAQKFQGRVTLTSDKSTSTAYMELSSLRSEDTAVYYCARGGPYGWYFDVWGQGTTVTVSS
site604	DG	N+1	56	H56	H64	False	CDR2	H	11178	11178_seq2	IGHV1-69*02	IGHV1	vibostolimab	Humanized	EVQLVQSGAEVKKPGSSVKVSCKASGYTFSSYVMHWVRQAPGQGLEWIGYIDPYNDGAKYAQKFQGRVTLTSDKSTSTAYMELSSLRSEDTAVYYCARGGPYGWYFDVWGQGTTVTVSS
site605	DG	N	31	L28	L34	False	CDR1	K	11304	11304_seq1	IGKV7-3*01	IGKV7	vilobelimab	Chimeric	DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMKWYQQKPGQPPKLLIYAASNLQSGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPYTFGGGTKLEIK
site606	DG	N+1	32	L29	L35	True	CDR1	K	11304	11304_seq1	IGKV7-3*01	IGKV7	vilobelimab	Chimeric	DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMKWYQQKPGQPPKLLIYAASNLQSGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPYTFGGGTKLEIK
site607	DG	N	100	H97	H109	False	CDR3	H	11304	11304_seq2	IGHV1-46*01	IGHV1	vilobelimab	Chimeric	QVQLQQSGPQLVRPGTSVKISCKASGYSFTTFWMDWVKQRPGQGLEWIGRIDPSDSESRLDQRFKDRATLTVDKSSSTVYMQLSSPTSEDSAVYYCARGNDGYYGFAYWGQGTLVTVSS
site608	DG	N+1	101	H98	H110	False	CDR3	H	11304	11304_seq2	IGHV1-46*01	IGHV1	vilobelimab	Chimeric	QVQLQQSGPQLVRPGTSVKISCKASGYSFTTFWMDWVKQRPGQGLEWIGRIDPSDSESRLDQRFKDRATLTVDKSSSTVYMQLSSPTSEDSAVYYCARGNDGYYGFAYWGQGTLVTVSS
site609	DG	N	53	H53	H59	True	CDR2	H	10989	10989_seq1	IGHV3-33*01	IGHV3	volagidemab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVMWYDGSNKDYVDSVKGRFTISRDNSKNTLYLQMNRLRAEDTAVYYCAREKDHYDILTGYNYYYGLDVWGQGTTVTVSS
site610	DG	N+1	54	H54	H62	True	CDR2	H	10989	10989_seq1	IGHV3-33*01	IGHV3	volagidemab	Human	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVMWYDGSNKDYVDSVKGRFTISRDNSKNTLYLQMNRLRAEDTAVYYCAREKDHYDILTGYNYYYGLDVWGQGTTVTVSS
site611	NG	N	54	H54	H62	False	CDR2	H	10272	10272_seq2	IGHV1-46*01	IGHV1	vonlerolizumab	Humanized	EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQGLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRSEDTAVYYCVLAPRWYFSVWGQGTLVTVSS
site612	NG	N+1	55	H55	H63	True	CDR2	H	10272	10272_seq2	IGHV1-46*01	IGHV1	vonlerolizumab	Humanized	EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQGLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRSEDTAVYYCVLAPRWYFSVWGQGTLVTVSS
site613	DG	N	53	H53	H59	True	CDR2	H	10730	10730_seq2	IGHV3-74*01	IGHV3	vopratelimab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYWMDWVRQAPGKGLVWVSNIDEDGSITEYSPFVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCTRWGRFGFDSWGQGTLVTVSS
site614	DG	N+1	54	H54	H62	True	CDR2	H	10730	10730_seq2	IGHV3-74*01	IGHV3	vopratelimab	Humanized	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYWMDWVRQAPGKGLVWVSNIDEDGSITEYSPFVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCTRWGRFGFDSWGQGTLVTVSS
site615	DG	N	55	H55	H63	False	CDR2	H	9226	9226_seq1	IGHV1-2*02	IGHV1	yttrium (90Y) clivatuzumab tetraxetan	Humanized	QVQLQQSGAEVKKPGASVKVSCEASGYTFPSYVLHWVKQAPGQGLEWIGYINPYNDGTQYNEKFKGKATLTRDTSINTAYMELSRLRSDDTAVYYCARGFGGSYGFAYWGQGTLVTVSS
site616	DG	N+1	56	H56	H64	True	CDR2	H	9226	9226_seq1	IGHV1-2*02	IGHV1	yttrium (90Y) clivatuzumab tetraxetan	Humanized	QVQLQQSGAEVKKPGASVKVSCEASGYTFPSYVLHWVKQAPGQGLEWIGYINPYNDGTQYNEKFKGKATLTRDTSINTAYMELSRLRSDDTAVYYCARGFGGSYGFAYWGQGTLVTVSS
site617	NG	N	54	H54	H62	True	CDR2	H	11797	11797_seq2	IGHV1-18*01	IGHV1	zansecimab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYNMVWVRQAPGQGLEWMGYIDPYNGGTGYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARTRDRYDVWYFDVWGQGTLVTVSS
site618	NG	N+1	55	H55	H63	True	CDR2	H	11797	11797_seq2	IGHV1-18*01	IGHV1	zansecimab	Humanized	QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYNMVWVRQAPGQGLEWMGYIDPYNGGTGYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARTRDRYDVWYFDVWGQGTLVTVSS
site619	DG	N	53	H53	H59	False	CDR2	H	11091	11091_seq2	IGHV1-46*01	IGHV1	zelminemab	Humanized	QVQLVESGAEVVKPGASVKVSCKASGFTFSRFAMHWVRQAPGQGLEWMGVISYDGGNKYYAESVKGRVTMTRDTSTSTLYMELSSLRSEDTAVYYCARGYDVLTGYPDYWGQGTLVTVSS
site620	DG	N+1	54	H54	H62	True	CDR2	H	11091	11091_seq2	IGHV1-46*01	IGHV1	zelminemab	Humanized	QVQLVESGAEVVKPGASVKVSCKASGFTFSRFAMHWVRQAPGQGLEWMGVISYDGGNKYYAESVKGRVTMTRDTSTSTLYMELSSLRSEDTAVYYCARGYDVLTGYPDYWGQGTLVTVSS
site621	NG	N	54	H54	H62	True	CDR2	H	11331	11331_seq1	IGHV1-3*01	IGHV1	zuberitamab	Chimeric	EVQLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSS
site622	NG	N+1	55	H55	H63	True	CDR2	H	11331	11331_seq1	IGHV1-3*01	IGHV1	zuberitamab	Chimeric	EVQLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSS
